Methods and compositions for treating cancer

A novel compound targeting kinase pathways in hormone receptor positive endometrial cancer, combined with estrogen blockers, effectively treats the cancer by inhibiting cell proliferation and overcoming resistance, with reduced side effects.

JP2024542205AInactive Publication Date: 2024-11-13オンコノヴァ セラピューティクス インコーポレイテッド
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024529542
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-18
Filing Date
2022-11-18
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for hormone receptor positive endometrial cancer, particularly those involving PI3K and MAPK pathways, face challenges in efficacy and resistance, necessitating new therapeutic approaches.

Method used

Administration of a therapeutically effective amount of a compound, such as 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or its pharmaceutically acceptable salts, potentially in combination with estrogen blockers like letrozole or megestrol acetate, to target kinase pathways and inhibit cell proliferation.

Benefits of technology

The compound demonstrates broad kinase inhibition, reducing tumor growth and overcoming resistance to CDK4/6 inhibitors, with lower side effects like neutropenia compared to FDA-approved inhibitors, offering a viable treatment option for hormone receptor positive endometrial cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542205000001_ABST
    Figure 2024542205000001_ABST
Patent Text Reader

Abstract

Disclosed herein is a method of treating endometrial cancer by administering to a subject a solid pharmaceutical composition comprising 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, alone or in combination with a second agent, such as letrozole. Provided herein are compositions and methods for treating endometrial cancer by administering to a subject in need of treatment a pharmaceutical composition, the pharmaceutical composition comprising a therapeutically effective amount of a compound described herein or a pharma- ceutically acceptable salt thereof, in a unit dosage form. In some embodiments, the method further comprises administering a second pharmaceutical composition comprising a therapeutically effective amount of a second compound, e.g., an estrogen blocker, in a unit dosage form.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] cross reference This application claims the benefit of U.S. Provisional Patent Application No. 63 / 280,948, filed November 18, 2021, the entirety of which is incorporated by reference herein. [Background technology]

[0002] background Endometrial cancer is the most common gynecological malignancy. The majority of endometrial cancers have alterations in both the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways.

[0003] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. Summary of the Invention [Means for solving the problem]

[0004] Summary of the Invention In some embodiments, the present disclosure provides a method of treating hormone receptor positive endometrial cancer in a subject in need of treatment, the method comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): [ka] A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 Ga-NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof, A method is provided.

[0005] In some embodiments, the present disclosure provides a method of treating endometrial cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I): [ka] A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 Ga-NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof, A method is provided.

[0006] In some embodiments, the disclosure provides a method of treating endometrial cancer, e.g., hormone receptor positive endometrial cancer, estrogen receptor positive endometrial cancer, progesterone receptor positive endometrial cancer, estrogen receptor positive, progesterone receptor positive endometrial cancer, in a subject in need of treatment, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I): [ka] A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5, -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O)2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 Ga-NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof, The subject has received a treatment other than the compound for endometrial cancer, e.g., hormone receptor positive endometrial cancer, estrogen receptor positive endometrial cancer, progesterone receptor positive endometrial cancer, estrogen receptor positive, progesterone receptor positive endometrial cancer, prior to administration. A method is provided.

[0007] In some embodiments, the disclosure provides a method of treating endometrial cancer, e.g., hormone receptor positive endometrial cancer, estrogen receptor positive endometrial cancer, progesterone receptor positive endometrial cancer, estrogen receptor positive, progesterone receptor positive endometrial cancer, in a subject in need of treatment, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I): [ka] A compound of the formula: During the ceremony, - R 1is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 Ga-NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof, Administering is once daily for at least four weeks; A method is provided.

[0008] In some embodiments, the disclosure provides a method of treating endometrial cancer, e.g., hormone receptor positive endometrial cancer, estrogen receptor positive endometrial cancer, progesterone receptor positive endometrial cancer, estrogen receptor positive, progesterone receptor positive endometrial cancer, in a subject in need of treatment, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I): [ka] A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 Ga-NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof, Administering (i) a period of 3 consecutive weeks of once-daily dosing, and ii) a one-week period without treatment immediately following the three-week period This is a four-week cycle. A method is provided.

[0009] In some embodiments, the present disclosure provides a method of treating endometrial cancer, e.g., hormone receptor positive endometrial cancer, estrogen receptor positive endometrial cancer, progesterone receptor positive endometrial cancer, estrogen receptor positive, progesterone receptor positive endometrial cancer, in a subject in need of treatment, the method comprising: (i) administering to a subject a therapeutically effective amount of a first compound having formula (I) [ka] A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 Ga-NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not A first compound, which is a compound or a pharma- ceutically acceptable salt thereof; and (ii) administering to the subject a therapeutically effective amount of a second compound. The present invention provides a method comprising:

[0010] In some embodiments, the disclosure provides a method of treating endometrial cancer, e.g., hormone receptor positive endometrial cancer, estrogen receptor positive endometrial cancer, progesterone receptor positive endometrial cancer, estrogen receptor positive, progesterone receptor positive endometrial cancer, in a subject in need of treatment, comprising orally administering to the subject a solid pharmaceutical composition, the solid pharmaceutical composition comprising 40 mg to 500 mg of a compound that is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, and the subject is administered the subject receives a treatment other than a compound for endometrial cancer, e.g., hormone receptor positive endometrial cancer, estrogen receptor positive endometrial cancer, progesterone receptor positive endometrial cancer, estrogen receptor positive, progesterone receptor positive endometrial cancer, the treatment is given after the subject is diagnosed with endometrial cancer, e.g., hormone receptor positive endometrial cancer, estrogen receptor positive endometrial cancer, progesterone receptor positive endometrial cancer, estrogen receptor positive, progesterone receptor positive endometrial cancer, the subject is unresponsive to the treatment prior to administering, and administering comprises orally administering, including once daily administration for three weeks.

[0011] In some embodiments, the disclosure provides a method of treating endometrial cancer, e.g., hormone receptor positive endometrial cancer, estrogen receptor positive endometrial cancer, progesterone receptor positive endometrial cancer, estrogen receptor positive, progesterone receptor positive endometrial cancer, in a subject in need of such treatment, comprising: (i) orally administering to the subject a solid pharmaceutical composition, the solid pharmaceutical composition comprising 40 mg to 500 mg of a compound that is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, and the subject is, prior to administration, administering a solid pharmaceutical composition to the subject, the solid pharmaceutical composition comprising 40 mg to 500 mg of a compound that is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate. and (ii) orally administering to the subject a therapeutically effective amount of letrozole, comprising administering orally once daily for three weeks.

[0012] In some embodiments, the disclosure provides a method of treating endometrial cancer, e.g., hormone receptor positive endometrial cancer, estrogen receptor positive endometrial cancer, progesterone receptor positive endometrial cancer, estrogen receptor positive, progesterone receptor positive endometrial cancer, in a subject in need thereof, comprising: (i) orally administering to the subject a solid pharmaceutical composition, the solid pharmaceutical composition comprising 40 mg to 500 mg of a compound that is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, and the subject is, prior to administration, diagnosed with endometrial cancer, e.g., hormone receptor positive endometrial cancer. and (ii) orally administering to the subject a therapeutically effective amount of megestrol acetate, wherein the subject has received a treatment other than a compound for endometrial cancer, e.g., hormone receptor positive endometrial cancer, estrogen receptor positive endometrial cancer, progesterone receptor positive endometrial cancer, estrogen receptor positive, progesterone receptor positive endometrial cancer, wherein the treatment is given after the subject has been diagnosed with endometrial cancer, e.g., hormone receptor positive endometrial cancer, estrogen receptor positive endometrial cancer, progesterone receptor positive endometrial cancer, estrogen receptor positive, progesterone receptor positive endometrial cancer, wherein the subject has been unresponsive to the treatment prior to administering, wherein administering comprises orally administering, comprising once daily administration for three weeks; and (ii) orally administering to the subject a therapeutically effective amount of megestrol acetate. [Brief description of the drawings]

[0013] [Figure 1] FIG. 1 shows the KinMap of CDK4 / 6 inhibitors: Compound 1, Comparator 1, Comparator 2 and Comparator 3.

[0014] [Diagram 2] FIG. 2 demonstrates that cancer cell lines treated with Compound 1 exhibited reduced neutropenia compared to cancer cell lines treated with Control 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] Detailed Description of the Disclosure Provided herein are compositions and methods for treating endometrial cancer by administering a pharmaceutical composition to a subject in need of treatment, the pharmaceutical composition comprising a therapeutically effective amount of the compound described herein or its pharmaceutically acceptable salt in unit dosage form.In some embodiments, the method further comprises administering a second pharmaceutical composition comprising a therapeutically effective amount of a second compound, for example, an estrogen blocker, in unit dosage form.

[0016] Compounds of the Disclosure The compounds disclosed herein have the formula: [ka] A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5(each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 Ga-NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2-C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof.

[0017] The compounds disclosed herein have the formula: [ka] A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; compound or a pharma- ceutically acceptable salt thereof.

[0018] The compounds disclosed herein have the formula: [ka] A pharma- ceutically acceptable salt of the compound of During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5, -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 can be a pharma- ceutically acceptable salt, in which R is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen.

[0019] The compounds disclosed herein have the formula: [ka] may be a lactate salt of the compound During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen.

[0020] In some embodiments, R 1 is cycloalkyl. In some embodiments, R 1 is C 3 ~C 8 In some embodiments, R 1 is unsubstituted cyclopentyl. In some embodiments, R 1 is a substituted cyclopentyl. In some embodiments, R 2 is CN. In some embodiments, R 3 is hydrogen.

[0021] In some embodiments, R 4 -NR 5 R 6 In some embodiments, R 5 and R 6 is hydrogen. 5 and R 6 One of R is phenyl. 5 and R 6 One of R is phenyl substituted with heterocyclyl. 5 and R 6 One of R is phenyl substituted with heterocyclyl, the heterocyclyl containing at least one ring nitrogen atom. 5 and R 6 One of them is C 3 ~C 8 In some embodiments, R is phenyl substituted with heterocyclyl. 5 and R 6 One of them is C 6 In some embodiments, R is phenyl substituted with heterocyclyl.5 and R 6 In some embodiments, one of R is phenyl substituted with piperazinyl, wherein the piperazinyl is unsubstituted or substituted. 5 and R 6 One of R is phenyl substituted with piperazinyl, wherein the piperazinyl is substituted with alkyl. 5 and R 6 One of the groups is phenyl substituted with 4-methylpiperazinyl.

[0022] In some embodiments, R 4 teeth, [ka] and During the ceremony, - R 7 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen; - R 8 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen; - R 9 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen.

[0023] In some embodiments, R7 is hydrogen. In some embodiments, R 8 is hydrogen. In some embodiments, R 9 is unsubstituted or substituted heterocyclyl. In some embodiments, R 9 is unsubstituted or substituted piperazinyl. In some embodiments, R 9 is piperazinyl substituted with alkyl. In some embodiments, R 9 is 4-methylpiperazinyl.

[0024] In some embodiments, the compound has formula (II): [ka] It is a compound of the formula:

[0025] In some embodiments, the compound has formula (III): [ka] A compound of the formula: During the ceremony, - Y is O, S or NR 11 and - Each R 10 are independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (which are unsubstituted or substituted, respectively) - R 11 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; - n is 0, 1, 2, 3, 4, 5, 6, 7, or 8; It is a compound.

[0026] In some embodiments, R 1 is cycloalkyl. In some embodiments, R 1 is C 3 ~C 8 In some embodiments, R 1 is unsubstituted cyclopentyl. In some embodiments, R 1 is a substituted cyclopentyl.

[0027] In some embodiments, Y is NR 11 In some embodiments, R 11 is alkyl. In some embodiments, R 11 In some embodiments, n is 0.

[0028] In some embodiments, the compound has the formula: [ka] The compound is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile (Compound 1), or a pharma- ceutically acceptable salt thereof.

[0029] In some embodiments, the compound is in the form of a salt formed by combining the compound with lactic acid. In some embodiments, the compound disclosed herein is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

[0030] Some moieties described herein may be substituted or unsubstituted. Non-limiting examples of optional substituents include hydroxyl, sulfhydryl, halogen, amino, nitro, nitroso, cyano, azide, sulfoxide, sulfone, sulfonamide, carboxyl, carboxaldehyde, imine, alkyl, halo-alkyl, alkenyl, halo-alkenyl, alkynyl, halo-alkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclyl, acyl, acyloxy, carbamate, amide, ureido, epoxy, and ester groups.

[0031] Non-limiting examples of alkyl groups include linear, branched, and cyclic alkyl groups. The alkyl group can be, for example, a substituted or unsubstituted C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49 , or C 50 It may be a group.

[0032] Non-limiting examples of straight chain alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl.

[0033] Branched alkyl groups include any straight chain alkyl group substituted with any number of alkyl groups. Non-limiting examples of branched alkyl groups include isopropyl, isobutyl, sec-butyl, and t-butyl.

[0034] Non-limiting examples of substituted alkyl groups include hydroxymethyl, chloromethyl, trifluoromethyl, aminomethyl, 1-chloroethyl, 2-hydroxyethyl, 1,2-difluoroethyl, and 3-carboxypropyl.

[0035] Non-limiting examples of cyclic alkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptlyl, and cyclooctyl groups. Cyclic alkyl groups also include fused, bridged, and spiro bicycles, as well as higher fused, bridged, and spiro systems. Cyclic alkyl groups may be substituted with any number of linear, branched, or cyclic alkyl groups. Non-limiting examples of cyclic alkyl groups include cyclopropyl, 2-methyl-cycloprop-1-yl, cycloprop-2-en-1-yl, cyclobutyl, 2,3-dihydroxycyclobut-1-yl, cyclobut-2-en-1-yl, cyclopentyl, cyclopent-2-en-1-yl, cyclopenta-2,4-dien-1-yl, cyclohexyl, cyclohex-2-en-1-yl, cycloheptyl, cyclooctanyl, 2,5-dimethylcyclopent-1-yl, 3,5-dichlorocyclohex-1-yl, 4- Examples include hydroxycyclohex-1-yl, 3,3,5-trimethylcyclohex-1-yl, octahydropentalenyl, octahydro-1H-indenyl, 3a,4,5,6,7,7a-hexahydro-3H-inden-4-yl, decahydroazulenyl, bicyclo-[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, 1,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.

[0036] Non-limiting examples of alkenyl and alkenylene groups include linear, branched, and cyclic alkenyl groups. The olefin(s) of the alkenyl group can be, for example, E, Z, cis, trans, terminal, or exo-methylene. The alkenyl or alkenylene group can be, for example, substituted or unsubstituted, C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11, C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49 , or C 50 Non-limiting examples of alkenyl and alkenylene groups include ethenyl, prop-1-en-1-yl, isopropenyl, but-1-en-4-yl, 2-chloroethenyl, 4-hydroxybuten-1-yl, 7-hydroxy-7-methyloct-4-en-2-yl, and 7-hydroxy-7-methylocta-3,5-dien-2-yl.

[0037] Non-limiting examples of alkynyl or alkynylene groups include linear, branched, and cyclic alkynyl groups. The triple bond of an alkylnyl or alkynylene group can be internal or terminal. An alkynyl or alkynylene group can be, for example, a substituted or unsubstituted C 2 , C 3 , C 4 , C 5 , C6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49 , or C 50 Non-limiting examples of alkynyl or alkynylene groups include ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, and 2-methyl-hex-4-yn-1-yl; 5-hydroxy-5-methylhex-3-yn-1-yl, 6-hydroxy-6-methylhept-3-yn-2-yl, and 5-hydroxy-5-ethylhept-3-yn-1-yl.

[0038] A halo-alkyl group can be any alkyl group substituted with any number of halogen atoms, such as fluorine, chlorine, bromine, and iodine atoms. A halo-alkenyl group can be any alkenyl group substituted with any number of halogen atoms. A halo-alkynyl group can be any alkynyl group substituted with any number of halogen atoms.

[0039] An alkoxy group can be, for example, an oxygen atom substituted with any alkyl, alkenyl, or alkynyl group. An ether or ether group comprises an alkoxy group. Non-limiting examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, and isobutoxy.

[0040] The aryl group may be heterocyclic or non-heterocyclic. The aryl group may be monocyclic or polycyclic. The aryl group may be substituted with any number of substituents described herein, such as hydrocarbyl groups, alkyl groups, alkoxy groups, and halogen atoms. Non-limiting examples of aryl groups include phenyl, toluyl, naphthyl, pyrrolyl, pyridyl, imidazolyl, thiophenyl, and furyl. Non-limiting examples of substituted aryl groups include 3,4-dimethylphenyl, 4-tert-butylphenyl, 4-cyclopropylphenyl, 4-diethylaminophenyl, 4-(trifluoromethyl)phenyl, 4-(difluoromethoxy)-phenyl, 4-(trifluoromethoxy)phenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-fluorophenyl, 2-chlorophenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 2-methylphenyl, 3-fluorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-methylphenyl, 4-methoxyphenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydro ... methoxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,4,5-trifluorophenyl, 2,4,6-trifluorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 2,3,4-trichlorophenyl, 2,3,5-trichlorophenyl, 2,3,6-trichlorophenyl, 2,4,5-trichlorophenyl, 3,4,5-trichlorophenyl, 2,4,6-trichlorophenyl, 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,Examples of the phenyl group include 6-dimethylphenyl, 2,3,4-trimethylphenyl, 2,3,5-trimethylphenyl, 2,3,6-trimethylphenyl, 2,4,5-trimethylphenyl, 2,4,6-trimethylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2,3-diethylphenyl, 2,4-diethylphenyl, 2,5-diethylphenyl, 2,6-diethylphenyl, 3,4-diethylphenyl, 2,3,4-triethylphenyl, 2,3,5-triethylphenyl, 2,3,6-triethylphenyl, 2,4,5-triethylphenyl, 2,4,6-triethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, and 4-isopropylphenyl.

[0041] Non-limiting examples of substituted aryl groups include 2-aminophenyl, 2-(N-methylamino)phenyl, 2-(N,N-dimethylamino)phenyl, 2-(N-ethylamino)phenyl, 2-(N,N-diethylamino)phenyl, 3-aminophenyl, 3-(N-methylamino)phenyl, 3-(N,N-dimethylamino)phenyl, 3-(N-ethylamino)phenyl, 3-(N,N-diethylamino)phenyl, 4-aminophenyl, 4-(N-methylamino)phenyl, 4-(N,N-dimethylamino)phenyl, 4-(N-ethylamino)phenyl, and 4-(N,N-diethylamino)phenyl.

[0042] Heterocycles can be any ring containing non-carbon ring atoms, such as N, O, S, P, Si, B, or any other heteroatom. Heterocycles can be substituted with any number of substituents, such as alkyl groups and halogen atoms. Heterocycles can be aromatic (heteroaryl) or non-aromatic. Non-limiting examples of heterocycles include pyrrole, pyrrolidine, pyridine, piperidine, succinamide, maleimide, morpholine, imidazole, thiophene, furan, tetrahydrofuran, pyran, and tetrahydropyran.

[0043] Non-limiting examples of heterocycles (heterocyclyls) include heterocyclic units having a single ring containing one or more heteroatoms, non-limiting examples of which include diazirinyl, aziridinyl, azetidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolinyl, oxathiazolidinonyl, oxazolidinonyl, hydantoinyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, piperidin-2-onyl, 2,3,4,5-tetrahydro-1H-pyran ... -azepinyl, 2,3-dihydro-1H-indole, and 1,2,3,4-tetrahydroquinoline), and ii) heterocyclic units having two or more rings, one of which is a heterocyclic ring (non-limiting examples of which include hexahydro-1H-pyrrolidinyl, 3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazolyl, 3a,4,5,6,7,7a-hexahydro-1H-indolyl, 1,2,3,4-tetrahydroquinolinyl, and decahydro-1H-cycloocta[b]pyrrolyl).

[0044] Non-limiting examples of heteroaryls include i) heteroaryl rings containing a single ring, non-limiting examples of which include 1,2,3,4-tetrazolyl, [1,2,3]triazolyl, [1,2,4]triazolyl, triazinyl, thiazolyl, 1H-imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, thiophenyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl, and 4-dimethylaminopyridinyl; and ii) heteroaryl rings containing two or more rings, non-limiting examples of which include 1,2,3,4-tetrazolyl, [1,2,3]triazolyl, [1,2,4]triazolyl, triazinyl, thiazolyl, 1H-imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, thiophenyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl, and 4-dimethylaminopyridinyl. Included are heteroaryl rings that contain multiple fused rings, one of which is a heteroaryl ring (non-limiting examples of which include 7H-purinyl, 9H-purinyl, 6-amino-9H-purinyl, 5H-pyrrolo[3,2-d]pyrimidinyl, 7H-pyrrolo[2,3-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, 4,5,6,7-tetrahydro-1-H-indolyl, quinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxy-quinolinyl, and isoquinolinyl).

[0045] Any of the compounds herein may be purified. The compounds herein may be at least 1% pure, at least 2% pure, at least 3% pure, at least 4% pure, at least 5% pure, at least 6% pure, at least 7% pure, at least 8% pure, at least 9% pure, at least 10% pure, at least 11% pure, at least 12% pure, at least 13% pure, at least 14% pure, at least 15% pure, at least 16% pure, at least 17% pure, at least 18% pure, at least 19% pure, at least 20% pure, at least 21% pure, at least 22% pure, at least 23% pure, at least 24% pure, at least 25% pure, at least 26% pure, at least 27% pure, at least 28% pure, at least 29% pure, at least 30% pure, at least 31% pure, at least 32% pure, at least 33% pure, at least 34% pure, at least 35% pure, at least 36% pure, at least 37% pure, at least 38% pure, at least 39% pure, at least 40% pure, at least 41% pure, at least 42% pure, at least 43% pure, at least 44% pure, at least 45% pure, at least 46% pure, at least 47% pure, at least 48% pure, at least 49% pure, at least 50% pure, at least 51% pure, at least 52% pure, at least 53% pure, at least 54% pure, at least 55% pure, at least 56% pure, at least 57% pure, at least 58% pure, at least 59% pure, at least 60% pure, at least 61% pure, at least 62% pure, at least 63% pure, at least pure, at least 23% pure, at least 24% pure, at least 25% pure, at least 26% pure, at least 27% pure, at least 28% pure, at least 29% pure, at least 30% pure, at least 31% pure, at least 32% pure, at least 33% pure, at least 34% pure, at least 35% pure, at least 36% pure, at least 37% pure, at least 38% pure, at least 39% pure, at least 40% pure, at least 41% pure, at least 42% pure, at least 43% pure, at least 44% pure pure, at least 45% pure, at least 46% pure, at least 47% pure, at least 48% pure, at least 49% pure, at least 50% pure, at least 51% pure, at least 52% pure, at least 53% pure, at least 54% pure, at least 55% pure, at least 56% pure, at least 57% pure, at least 58% pure, at least 59% pure, at least 60% pure, at least 61% pure, at least 62% pure, at least 63% pure, at least 64% pure, at least 65% pure, at least 66% pure , at least 67% pure, at least 68% pure, at least 69% pure, at least 70% pure, at least 71% pure, at least 72% pure, at least 73% pure, at least 74% pure, at least 75% pure, at least 76% pure, at least 77% pure, at least 78% pure, at least 79% pure, at least 80% pure, at least 81% pure, at least 82% pure, at least 83% pure, at least 84% pure, at least 85% pure, at least 86% pure, at least 87% pure, at least 88% pure,It may be at least 89% pure, at least 90% pure, at least 91% pure, at least 92% pure, at least 93% pure, at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, at least 99.1% pure, at least 99.2% pure, at least 99.3% pure, at least 99.4% pure, at least 99.5% pure, at least 99.6% pure, at least 99.7% pure, at least 99.8% pure, or at least 99.9% pure.

[0046] Pharmaceutically acceptable salts The method disclosed herein provides for the use of any compound described herein with pharmaceutically acceptable salt.Pharmaceutically acceptable salt includes, for example, acid addition salt and base addition salt.The acid that is added to the compound to generate the acid addition salt can be organic acid or inorganic acid.The base that is added to the compound to generate the base addition salt can be organic base or inorganic base.

[0047] Acid addition salts may result from the addition of an acid to a compound disclosed herein. In some embodiments, the acid is organic. In some embodiments, the acid is inorganic. In some embodiments, the acid is lactic acid, salicylic acid, tartaric acid, ascorbic acid, gentisinic acid, gluconic acid, glucaronic acid, saccaric acid, formic acid, benzoic acid, glutamic acid, pantothenic acid, acetic acid, propionic acid, butyric acid, fumaric acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, oxalic acid, maleic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, nitrous acid, sulfuric acid, sulfurous acid, phosphoric acid, or isonicotinic acid. In some embodiments, the salt is an acid addition salt with lactic acid. In some embodiments, the salt is the acid addition salt of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile with lactic acid.

[0048] In some embodiments, the salt is lactate, salicylate, tartrate, ascorbate, gentisinate salt, gluconate, glucuronate salt, saccharate, formate, benzoate, glutamate, pantothenate, acetate, propionate, butyrate, fumarate, succinate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, citrate, oxalate, maleate, hydrochloride, hydrobromide, hydroiodide, nitrate, nitrite, sulfate, sulfite, phosphate, isonicotinate. In some embodiments, the salt is lactate. In some embodiments, the salt is monolactate. In some embodiments, the salt is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

[0049] Metal salts can result from the addition of inorganic bases to the compounds disclosed herein. Inorganic bases consist of a metal cation paired with a basic counterion, such as, for example, hydroxide, carbonate, bicarbonate, or phosphate. The metal can be an alkali metal, an alkaline earth metal, a transition metal, or a main group metal. In some embodiments, the metal is lithium, sodium, potassium, cesium, cerium, magnesium, manganese, iron, calcium, strontium, cobalt, titanium, aluminum, copper, cadmium, or zinc.

[0050] In some embodiments, the metal salt is a lithium salt, a sodium salt, a potassium salt, a cesium salt, a cerium salt, a magnesium salt, a manganese salt, an iron salt, a calcium salt, a strontium salt, a cobalt salt, a titanium salt, an aluminum salt, a copper salt, a cadmium salt, or a zinc salt.

[0051] Treatment method Phosphoinositide 3-kinase (PI3 kinase or PI3K), protein kinase B (AKT) and mitogen-activated protein kinase (MAPK) pathways are central to many signal transduction pathways and are often deregulated in cancers, including endometrial cancer. In some embodiments, the compounds described herein can down-modulate these kinase pathways or parts thereof, such as cyclin-dependent kinases (CDKs). In some embodiments, overexpression of CDKs, such as CDK4 / 6, causes cell cycle deregulation in cancer. In some embodiments, modulation of kinase pathways can result in the prevention of proliferation signal reception in cells, thus halting tumor growth.

[0052] In some embodiments, the compounds described herein can be inhibitors of the cyclin-dependent kinase protein CDK4. In some embodiments, the compounds described herein can be inhibitors of CDK6. In some embodiments, the compounds described herein can be inhibitors of CDK1. In some embodiments, the compounds described herein can be inhibitors of CDK2. In some embodiments, the compounds described herein can be inhibitors of CDK7. In some embodiments, the compounds described herein can be inhibitors of CDK9. In some embodiments, the compounds described herein can be inhibitors of CDK16. In some embodiments, the compounds described herein can be inhibitors of CDK17. In some embodiments, the compounds described herein can be inhibitors of CDK4 / 6. In some embodiments, the compounds described herein can be used to treat cancers where other CDK4 / 6 inhibitors have failed. In some embodiments, the compounds described herein can be inhibitors of colony-stimulating factor receptor 1 (CSF1R). In some embodiments, the compounds described herein can be inhibitors of the proto-oncogene receptor tyrosine kinase KIT. In some embodiments, the compounds described herein are inhibitors of AMPK-related protein kinase 5 (ARK5 or NUAK1) protein. ARK5 regulates Atk-dependent cell survival and migration (e.g., formation of metastases) through inhibition of cell metabolism. ARK5 overexpression is found in multiple tumors and is associated with poor prognosis in metastatic breast cancer, multiple myeloma and hepatocellular carcinoma. In some embodiments, inhibition of ARK5 induces cell death through the PI3K / AKT / mTOR pathway. In some embodiments, the combination of CDK and ARK5 inhibitors has synergistic effects in cancer cells by simultaneously inhibiting cell cycle (cytostatic) and cell metabolism (cytotoxicity) through CDK and ARK5, respectively.

[0053] In some embodiments, the inclusion of ARK5 in the functional activity profile of the compounds described herein overcomes the loss of retinoblastoma function and the emergence of resistance to CDK4 / 6 inhibitors due to C-Myc overexpression.C-Myc expression is dependent on ARK5 activity and is involved in the pathogenesis of certain tumors.In some embodiments, the dual inhibitory effect of the compounds described herein provides a therapeutic strategy to optimize the efficacy of CDK4 / 6 inhibition and reduce the emergence of resistance. The present disclosure provides methods for the use of the compounds disclosed herein, for example, to treat cancer.

[0054] In some embodiments, compounds disclosed herein, such as 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile (Compound 1) or a pharma- ceutically acceptable salt thereof, can be active in multiple tumor types with acceptable and differentiated safety profiles. FIG. 2 shows that in preclinical models, Compound 1 caused less neutropenia compared to FDA-approved CDK4 / 6 inhibitors (Comparative Control 1 in Table 1). For CDK4 and CDK6, Compound 1 had comparable ICs to FDA-approved CDK4 / 6 inhibitors (Comparative Controls 1, 2, and 3 in Table 1). 50 Compound 1 also had significantly lower IC values ​​for CSF1R, ARK5, and KIT than Control 1, Control 2, and Control 3. 50 Compound (1) had significantly lower IC values ​​(1 to 3 orders of magnitude lower) for CDK1, CDK2, CDK7, CDK9, CDK16, and CDK17 than Control 1 and Control 2. 50 values ​​(1-3 orders of magnitude lower).

[0055] In some embodiments, the compounds disclosed herein, e.g., Compound 1, exhibit a broader inhibition profile compared to kinase inhibitors that are not Compound 1, e.g., as determined by KinMap (Figure 1).

[0056] The methods disclosed herein can be used to treat, for example, infectious disease, proliferative disease, cancer, solid tumor, or liquid tumor.Non-limiting examples of tumors treatable by the combination of compounds described herein include solid tumors, solid tumors that are refractory to previous treatment with conventional chemotherapy, and solid tumors that respond to initial chemotherapy but then recur.In some embodiments, the tumor is an endometrial cancer tumor.

[0057] Tumor response according to the methods disclosed herein can be measured based on the Response Evaluation Criteria in Solid Tumors (RECIST) classification of response. To use RECIST, there must be at least one tumor that can be measured by x-ray, CT scan or MRI scan. RECIST assigns four categories of response: complete response (CR), partial response (PR), progressive disease (PD) and stable disease (SD). Important features of RECIST include the definition of the minimum size of measurable lesions, instructions on the number of lesions to follow, and the use of a one-dimensional rather than two-dimensional, scale for the overall assessment of tumor burden.

[0058] In some embodiments, the present disclosure provides a method of treating endometrial cancer in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, the present disclosure provides a method of treating endometrial cancer in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma-ceutically acceptable salt thereof. In some embodiments, the disclosure provides a method of treating endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

[0059] In some embodiments, the endometrial cancer is a hormone receptor positive endometrial cancer. In some embodiments, the present disclosure provides a method for treating hormone receptor positive endometrial cancer in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a method for treating hormone receptor positive endometrial cancer in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically acceptable salt thereof. In some embodiments, the disclosure provides a method of treating hormone receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

[0060] In some embodiments, the endometrial cancer is a progesterone receptor positive endometrial cancer. In some embodiments, the present disclosure provides a method of treating progesterone receptor positive endometrial cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a method of treating progesterone receptor positive endometrial cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically acceptable salt thereof. In some embodiments, the disclosure provides a method of treating progesterone receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

[0061] In some embodiments, the endometrial cancer is estrogen receptor positive endometrial cancer. In some embodiments, the present disclosure provides a method of treating estrogen receptor positive endometrial cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a method of treating estrogen receptor positive endometrial cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically acceptable salt thereof. In some embodiments, the disclosure provides a method of treating estrogen receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

[0062] In some embodiments, the endometrial cancer is estrogen receptor positive, progesterone receptor positive (ER+ / PR+) endometrial cancer. In some embodiments, the present disclosure provides a method of treating ER+ / PR+ endometrial cancer in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a method of treating ER+ / PR+ endometrial cancer in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically acceptable salt thereof. In some embodiments, the disclosure provides a method of treating ER+ / PR+ endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

[0063] In some embodiments, the endometrial cancer is progesterone receptor positive (PR+) endometrial cancer. In some embodiments, the present disclosure provides a method of treating PR+ endometrial cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a method of treating PR+ endometrial cancer in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically acceptable salt thereof. In some embodiments, the disclosure provides a method of treating PR+ endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

[0064] In some embodiments, the administering includes an additional treatment, e.g., a second-line, third-line, fourth-line, fifth-line, sixth-line, or seventh-line treatment. In some embodiments, the subject has received a treatment other than the compound for endometrial cancer (e.g., hormone receptor positive endometrial cancer) prior to the administering. In some embodiments, the treatment is given after the subject is diagnosed with endometrial cancer. In some embodiments, the treatment is given after the subject is diagnosed with hormone receptor positive endometrial cancer. In some embodiments, the treatment is given after the subject is diagnosed with estrogen receptor positive endometrial cancer. In some embodiments, the subject does not respond to the treatment. In some embodiments, the subject has experienced a recurrence of endometrial cancer after the treatment. In some embodiments, the subject has experienced a recurrence of hormone receptor positive endometrial cancer after the treatment. In some embodiments, the subject has experienced a recurrence of estrogen receptor positive endometrial cancer after the treatment.

[0065] Combination therapy The present disclosure also provides combinations of a compound disclosed herein, e.g., 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, with an estrogen blocker and / or an aromatase inhibitor, e.g., letrozole, and methods for using such.

[0066] In some embodiments, a compound of the present disclosure, such as a compound of formula (I), for example, 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, is administered in combination with a second compound, for example, a drug. In some embodiments, a compound of the present disclosure, such as a compound of formula (I), for example, 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, is administered in combination with an estrogen receptor modulator. In some embodiments, the compounds of the present disclosure, such as compounds of formula (I), for example, 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, are administered in combination with an estrogen receptor blocker, for example, an aromatase inhibitor, for example, letrozole. In some embodiments, the compounds of the present disclosure, such as compounds of formula (I), for example, 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, are administered in combination with a progestin, for example, megestrol or an ester thereof (e.g., megestrol acetate). In some embodiments, a compound of the disclosure, such as a compound of formula (I), such as 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile, is administered in combination with an estrogen receptor degrader.In some embodiments, a compound of the present disclosure, such as a compound of formula (I), for example, 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, is administered in combination with an angiogenesis inhibitor. In some embodiments, a compound of the present disclosure, such as a compound of formula (I), for example, 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, is administered in combination with a vascular endothelial growth factor (VEGF) inhibitor. In some embodiments, a compound of the disclosure, such as a compound of formula (I), such as 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile, or a pharma- ceutically acceptable salt thereof, is administered in combination with a phosphoinositide 3-kinase (PI3K) inhibitor.

[0067] Estrogen receptor blockers Estrogen stimulates or sustains the growth of some cancers (e.g., endometrial cancer). Treatment of endometrial cancer, which is considered to be hormone-responsive (e.g., estrogen and / or progesterone receptor positive), aims to reduce estrogen levels or inhibit estrogen effects. In some embodiments, these interventions result in a reduction in tumor burden or a delay in tumor growth progression.

[0068] Estrogen blockers block the production of estrogen (e.g., estradiol) or prevent estrogen (e.g., estradiol) from mediating biological effects in the body. Estrogen blockers act by blocking estrogen receptors and / or by directly inhibiting or suppressing estrogen production. Estrogen blockers are divided into classes according to whether they reduce the production of estrogen (aromatase inhibitors and antigonadotropins) or whether they reduce the response to estrogen (antiestrogens and estrogen antagonists). By producing less estrogen or blocking the response to estrogen, estrogen blockers slow or inhibit the growth of cancer cells (e.g., endometrial cells, uterine cells) that require estrogen to stimulate their growth. Non-limiting examples of estrogen blockers include aromatase inhibitors such as letrozole (Femara), anastrozole (Arimidex), exemestane (Aromasin), tamoxifen, testolactone (Teslac), ethamoxytriphetol, clomiphene, and raloxifene.

[0069] Non-limiting examples of cells whose activity can be modulated by combination therapy of the compounds described herein and estrogen blockers include secretory cells, ciliated cells, basal cells, erythroid cells, mesenchymal cells, pluripotent mesenchymal cells, predecidual cells, epithelial cells, histiocytes, granulocytes, glandular cells, stromal cells, normal endometrial cells (NEMC), atypical endometrial cells (AEMC), and endometrial carcinoma cells (EMCC).

[0070] Non-limiting examples of tumors treatable by the combination of the compounds described herein and estrogen blockers include solid tumors, solid tumors that are refractory to previous treatment with conventional chemotherapy, and solid tumors that respond to initial chemotherapy and subsequently recur, e.g., as evidenced by disease progression.

[0071] Non-limiting examples of cancers treatable by the combination of the compounds described herein and estrogen blockers include endometrial cancer, endometrial cancer that is hormone receptor positive (HR+), endometrial cancer that is estrogen receptor positive (ER+), endometrial cancer that is estrogen receptor positive, progesterone receptor positive (ER+ / PR+), progesterone receptor positive (PR+), endometrial cancer that is refractory to previous treatment with conventional chemotherapy, and endometrial cancer that responds to initial chemotherapy but subsequently recurs.

[0072] Aromatase inhibitors In postmenopausal women, estrogen is derived primarily from the action of the aromatase enzyme, which converts adrenal androgens (e.g., androstenedione and testosterone) to estrone and estradiol. Suppression of estrogen biosynthesis in peripheral and cancer tissues is achieved by inhibiting the aromatase enzyme.

[0073] Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system. It inhibits the conversion of androgens to estrogens. Letrozole selectively inhibits gonadal steroid production but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis. Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction in estrogen biosynthesis. Treatment of women with letrozole significantly reduces serum estrone, estradiol, and estrone sulfate.

[0074] The structure of letrozole is depicted below. [ka] 4,4'-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile. Pharmaceutically acceptable salts of 4,4'-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile can also be used.

[0075] Progestins Progestin is a synthetic form of the naturally occurring hormone progesterone. Progestin counteracts the effects of estrogen in the body and functions similarly to estrogen blockers. Non-limiting examples of progestin include megestrol acetate, acetomepregenol, chlormadinone acetate, cyproterone acetate, danazol, drospirenone, gestrinone, levonorgestrel, medrogestone, norethisterone, norethisterone acetate, norgestrel, oxendrone, osaterone acetate, trimegestone, norethindrone, norethindrone acetate, norethynodrel, ethynodiol diacetate, third desogestrel, gestodene, norgestimate, dienogest, nestorone, and nomegestrol acetate.

[0076] Megestrol acetate is a synthetic derivative of progesterone. It binds to progesterone receptors and alters the hormone balance in the body, which may inhibit or stop estrogen-related cancers.

[0077] The structure of megestrol acetate is depicted below. [ka] 17-Hydroxy-6-methyl pregna-4,6-diene-3,20-dione acetate.

[0078] Selective estrogen receptor degrading factor Selective estrogen receptor degraders or down-regulators (SERDs) can bind to the estrogen receptor and degrade and thus down-regulate it. SERDs are used with other similar classes of drugs, such as estrogen blockers and aromatase inhibitors, to treat estrogen receptor-sensitive or progesterone receptor-sensitive cancers.

[0079] Angiogenesis inhibitors and vascular endothelial growth factor inhibitors Angiogenesis inhibitors interfere with blood vessel formation.Normally, the angiogenesis stimulating and inhibiting effects of such chemical signals are balanced so that blood vessels are formed only when and where they are needed.However, such signals can become unbalanced and cause increased blood vessel growth, which can lead to abnormal conditions or diseases, such as cancer.

[0080] Vascular endothelial growth factor (VEGF) is an angiogenic factor that is a growth factor for vascular endothelial cells. When VEGF and other endothelial growth factors bind to receptors on endothelial cells, they initiate signals within the cells that promote the growth and survival of new blood vessels.

[0081] Angiogenesis inhibitors interfere with various steps in blood vessel growth. Some angiogenesis inhibitors are monoclonal antibodies that specifically recognize and bind VEGF and block the binding of VEGF to VEGF receptors. Other angiogenesis inhibitors bind to VEGF, VEGF receptors, other receptors on the surface of endothelial cells, or other proteins in downstream signaling pathways. Some angiogenesis inhibitors are immunomodulatory drugs (drugs that stimulate or suppress the immune system) that also have antiangiogenic properties. Non-limiting examples of VEGF inhibitors include bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent), nilotinib (Tasigna), pazopanib (Votrient), and dasatinib (Sprycel).

[0082] PI3K inhibitors Phosphoinositide 3-kinase (PI3K) inhibitors inhibit one or more of the phosphoinositide 3-kinase enzymes. Such enzymes form part of the PI3K / AKT / mTOR pathway, a pathway involved in cell growth and survival, as well as other processes that are frequently activated in many cancers. By inhibiting such enzymes, PI3K inhibitors cause cell death, inhibit the proliferation of malignant cells, and interfere with some signaling pathways. PI3K inhibitors are usually given to treat certain cancers that have relapsed or are unresponsive to other cancer treatments. Non-limiting examples of PI3K inhibitors include alpelisib, copanlisib, duvelisib, and idelalisib.

[0083] Administration of Compounds of the Disclosure compound 1 The compounds disclosed herein, such as 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile (Compound 1), can be formulated as a capsule. The capsule can be a hard capsule. The capsule can be a soft capsule. The capsule can be a soft gelatin capsule. In some embodiments, the compounds disclosed herein can be formulated as a hard capsule, the hard capsule containing 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate in an amount equivalent to 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile. Alternatively, the compounds disclosed herein can be formulated as a tablet.

[0084] In some embodiments, the disclosure provides a pharmaceutical composition comprising 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof in a unit dosage form in an amount equivalent to 40 mg of a compound described herein.

[0085] In some embodiments, the disclosure provides a pharmaceutical composition comprising 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof in a unit dosage form in an amount equivalent to 60 mg of a compound described herein.

[0086] In some embodiments, the disclosure provides a pharmaceutical composition comprising an amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate equivalent to 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile in a unit dosage form.

[0087] In some embodiments, the disclosure provides a pharmaceutical composition comprising 48.4 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate in a unit dosage form.

[0088] In some embodiments, 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt is administered in an oral capsule that is swallowed with water in the morning in a fasted state at least 1 hour before ingesting food. In some embodiments, the morning dose is taken 1 hour before ingesting food after an overnight fast. In some embodiments, the compounds described herein are administered daily. In some embodiments, the compounds described herein are administered daily for 4 weeks. In some embodiments, the compounds described herein are administered in a 4-week cycle (i) for a consecutive 3-week period of once-daily administration; and (ii) for a 4-week period immediately followed by a week of no administration.

[0089] Letrozole The compounds disclosed herein, such as letrozole, can be formulated as tablets. In some embodiments, letrozole can be formulated as tablets, which contain a therapeutically effective amount of letrozole and pharma- ceutically acceptable excipients in a unit dosage form.

[0090] In some embodiments, letrozole is provided as a 2.5 mg tablet for oral administration. The tablet may be colored, for example, yellow, and may be uncoated or film-coated. Inactive ingredients may include colloidal silicon dioxide, iron (II) oxide, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, corn starch, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, talc, and titanium dioxide. In some embodiments, letrozole is given in a dose of one 2.5 mg tablet administered once a day without regard to food.

[0091] Megestrol acetate The compounds disclosed herein, for example, megestrol acetate, can be formulated as a suspension, for example, a suspension suitable for oral administration. In some embodiments, megestrol acetate oral suspension contains 625mg of megestrol acetate per 5mL (125mg / mL). In some embodiments, megestrol acetate oral suspension contains 800mg per 20mL (40mg / mL). In some embodiments, megestrol acetate oral suspension contains one or more of the following inactive ingredients: alcohol (up to 0.06% v / v), lime flavor, citric acid monohydrate, sodium decusate, hydroxypropyl methylcellulose, natural and artificial lemon flavor, purified water, sodium benzoate, sodium citrate dihydrate, and sucrose.

[0092] In some embodiments, megestrol acetate can be formulated as a tablet. In some embodiments, the tablet contains 20mg megestrol acetate. In some embodiments, the tablet contains 40mg megestrol acetate. In some embodiments, megestrol acetate tablet contains one or more of the following inactive ingredients: acacia spray-dried, colloidal silicon dioxide, corn starch, calcium hydrogen phosphate dihydrate powder, lactose hydrous impalpable, magnesium stearate, and pregelatinized starch.

[0093] Pharmaceutical Compositions The pharmaceutical composition of the present disclosure may be a combination of any pharmaceutical compound described herein with other chemical components, such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, and / or excipients. The pharmaceutical composition may be administered in a therapeutically effective amount as a pharmaceutical composition by various forms and routes, including, for example, intravenous, subcutaneous, intramuscular, oral, parenteral, ophthalmic, subcutaneous, transdermal, nasal, vaginal, and topical administration. The pharmaceutical composition facilitates the administration of the compound to an organism. The pharmaceutical composition may be administered in a therapeutically effective amount as a pharmaceutical composition by various forms and routes, including, for example, intravenous, subcutaneous, intramuscular, inhalation, oral, parenteral, ophthalmic, otic, subcutaneous, transdermal, nasal, intravitreal, intratracheal, intrapulmonary, transmucosal, vaginal, and topical administration.

[0094] The formulation may be modified depending on the route of administration selected. Pharmaceutical compositions containing the compounds described herein can be prepared, for example, by a process of mixing, dissolving, emulsifying, encapsulating, entrapping, or compressing.

[0095] Non-limiting examples of dosage forms suitable for use in the methods disclosed herein include feed, food, pellets, lozenges, liquids, elixirs, aerosols, inhalants, sprays, powders, tablets, pills, capsules, gels, geltabs, nanosuspensions, nanoparticles, microgels, suppositories, troches, aqueous or oily suspensions, ointments, patches, lotions, dentifrices, emulsions, creams, drops, dispersible powders or granules, emulsions in hard or soft gel capsules, syrups, phytoceuticals, nutraceuticals, and any combination thereof.

[0096] Pharmaceutical compositions can be formulated by combining active compounds with pharma- ceutically acceptable carriers or excipients.Non-limiting examples of pharma-ceutically acceptable excipients suitable for use in the methods disclosed herein include granulating agents, binders, lubricants, disintegrants, sweeteners, glidants, anti-adhesive agents, antistatic agents, surfactants, antioxidants, gums, coating agents, colorants, flavoring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifiers, antimicrobial agents, plant cellulosic materials, and spheronization agents, and any combination thereof.

[0097] Non-limiting examples of pharma- ceutically acceptable carriers include saline solution, Ringer's solution and dextrose solution.Further carriers include sustained-release preparations such as semipermeable matrices of solid hydrophobic polymers containing the compounds disclosed herein, which matrices are in the form of shaped articles, such as films, liposomes, microparticles, and microcapsules.

[0098] For oral administration, pharmaceutical compositions can be formulated by combining active compounds with pharma- ceutically acceptable carriers or excipients to form a unit dosage form that can be solid or liquid. Non-limiting examples of oral solid forms include tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, or suspensions for oral ingestion by subjects. Pharmaceutical preparations for oral use can be obtained by mixing one or more solid excipients with one or more compounds described herein, grinding the resulting mixture as necessary, and processing the mixture of granules after adding suitable auxiliaries as required to obtain tablet or dragee cores. The cores can be provided with suitable coatings. For this purpose, concentrated sugar solutions can be used. The solutions can contain excipients such as gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. For example, dyestuffs or pigments can be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0099] Orally usable pharmaceutical preparations include push-fit capsules made of gelatin, and sealed soft capsules made of gelatin and plasticizers, such as glycerol or sorbitol. Orally usable pharmaceutical preparations include coated and uncoated tablets. In some embodiments, the capsule includes a hard gelatin capsule, which includes one or more of pharmaceutical bovine gelatin and vegetable gelatin. The gelatin can be treated with alkali. The capsule or tablet can contain the active ingredient in a mixture with a filler, such as lactose, a binder, such as starch, or a lubricant, such as talc or magnesium stearate, and a stabilizer. In soft capsules, the active compound can be dissolved or suspended in a suitable liquid, such as fatty oils, liquid paraffin, or liquid polyethylene glycol. Stabilizers can be added. All preparations for oral administration are provided in dosages suitable for such administration.

[0100] For oral administration in liquid unit dosage form, pharmaceutical compositions can be formulated by combining active compounds with pharma- ceutical acceptable carriers or excipients.Such carriers can be used to formulate tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, or suspensions for oral ingestion by subjects.Non-limiting examples of solvents used in oral dissolving formulations can include water, ethanol, isopropanol, saline, saline, DMSO, dimethylformamide, potassium phosphate buffer, phosphate buffered saline (PBS), sodium phosphate buffer, 4-2-hydroxyethyl-1-piperazineethanesulfonic acid buffer (HEPES), 3-(N-morpholino)propanesulfonic acid buffer (MOPS), piperazine-N,N'-bis(2-ethanesulfonic acid) buffer (PIPES), and saline sodium citrate buffer (SSC). Non-limiting examples of co-solvents used in orally soluble formulations can include sucrose, urea, cremaphor, DMSO, and potassium phosphate buffer.

[0101] Parenteral injections may be formulated for bolus injection or continuous infusion. Pharmaceutical compositions may be in a form suitable for parenteral injection as sterile suspensions, solutions, or emulsions in oily or aqueous vehicles such as saline or water for injection, and may contain formulatory agents such as suspending, stabilizing, and / or dispersing agents. Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compound in water-soluble form. Suspensions of the active compound may be prepared as oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate or triglycerides, or liposomes. Suspensions may also contain suitable stabilizers or agents that increase the solubility of the compound to allow for the preparation of highly concentrated solutions. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, for example sterile pyrogen-free water, before use.

[0102] The active compounds may be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams, and ointments. Such pharmaceutical compositions can contain solubilizers, stabilizers, tonicity enhancing agents, buffers, and preservatives. The compounds of the present disclosure can be applied topically to the skin of a subject, or to a body cavity, such as the mouth, vagina, bladder, cranial, spinal, thoracic, or pelvic cavity. The compounds of the present disclosure can be applied to any accessible body cavity.

[0103] The compounds can also be formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, and synthetic polymers such as polyvinylpyrrolidone and PEG. Suppository forms of the compositions may use low melting waxes such as mixtures of fatty acid glycerides, optionally in combination with cocoa butter.

[0104] For buccal or sublingual administration, the compositions may be tablets, lozenges, or gels.

[0105] Suitable formulations for transdermal administration of active compounds can use transdermal delivery devices and transdermal delivery patches, and can be lipophilic emulsions or buffered aqueous solutions dissolved or dispersed in polymers or adhesives. Such patches can be constructed for continuous, pulsatile, or on-demand delivery of pharmaceutical compounds. Transdermal delivery can be achieved by iontophoretic patches. Transdermal patches can provide controlled delivery. Absorption rate can be slowed by using a rate-limiting membrane or by trapping the compound within a polymer matrix or gel. Absorption enhancers can be used to increase absorption. Absorption enhancers or carriers can include pharma- ceutically acceptable absorbent solvents that aid passage through the skin. For example, transdermal devices can be in the form of a dressing, including a backing member, a reservoir containing the compound and carrier, a rate-limiting barrier for delivering the compound to the subject's skin at a controlled, predetermined rate over an extended period of time, and an adhesive for fixing the device to the skin or eye.

[0106] For administration by inhalation, the active compound may be in a form as an aerosol, vapor, mist, or powder. Inhalation may be via nasal delivery, oral delivery, or both.

[0107] Nasal or intranasal administration involves insufflation of compound through the nose, for example, nasal drops and nasal spray.This administration route can produce local and / or systemic effects.For nose-to-lung delivery of the compounds described herein, an inhaler or insufflator device can be used.

[0108] The pharmaceutical composition can be administered in a local or systemic manner, for example, by injecting the compound directly into an organ, optionally in a depot or sustained release formulation or implant.The pharmaceutical composition can be provided in the form of a fast release formulation, an extended release formulation, or an intermediate release formulation.The fast release form can provide immediate release.The extended release formulation can provide controlled release or sustained delayed release.

[0109] When practicing the method or use of treatment provided herein, a therapeutically effective amount of the compound described herein is administered in a pharmaceutical composition to a subject having a disease or condition to be treated.In some embodiments, the subject is a mammal, such as a human.The therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used, and other factors.The compound can be used alone or in combination with one or more therapeutic agents as a component of a mixture.

[0110] The method of preparing a composition comprising the compound described herein includes formulating the compound with one or more inert pharma- ceutically acceptable excipients or carriers to form a solid, semi-solid, or liquid composition. Solid compositions include, for example, powders, tablets, dispersible granules, capsules, and cachets. Liquid compositions include, for example, solutions in which the compound is dissolved, emulsions containing the compound, or solutions containing liposomes, micelles, or nanoparticles containing the compound described herein. Semi-solid compositions include, for example, gels, suspensions, and creams. The composition may be a liquid solution or suspension, a solid form suitable for dissolving or suspending in liquid before use, or an emulsion. These compositions may also contain small amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and other pharma- ceutical acceptable additives.

[0111] Non-limiting examples of dosage forms suitable for use in the present disclosure include liquids, powders, gels, nanosuspensions, nanoparticles, microgels, aqueous or oily suspensions, emulsions, and any combination thereof.

[0112] Non-limiting examples of dosage forms suitable for use in the present disclosure include binders, disintegrants, anti-adhesives, antistatic agents, surfactants, antioxidants, coatings, colorants, plasticizers, preservatives, suspending agents, emulsifiers, antimicrobial agents, spheronization agents, solubilizers, stabilizers, tonicity enhancers, buffers, and any combination thereof. Non-limiting examples of pharma- ceutically acceptable excipients suitable for use in the methods disclosed herein include.

[0113] The composition of the present invention may be, for example, an immediate release form or a controlled release formulation. An immediate release formulation may be formulated to make the compound act quickly. Non-limiting examples of immediate release formulations include formulations that are easily soluble. A controlled release formulation may be a pharmaceutical formulation in which the release rate and release profile of active agent are adapted to meet physiological and chronotherapeutic requirements, or are formulated to provide the release of active agent at a programmed rate. Non-limiting examples of controlled release formulations include granules, delayed release granules, hydrogels (e.g., synthetic or natural origin), other gelling agents (e.g., gel-forming dietary fibers), matrix-based formulations (e.g., formulations that include polymeric materials in which at least one active ingredient is dispersed), granules in a matrix, polymer mixtures, and granular agglomerates.

[0114] In some cases, the controlled release formulation is a delayed release form.The delayed release form may be formulated to delay the action of compound for a long period of time.The delayed release form may be formulated to delay the release of the effective dose of one or more compounds for, for example, about 4, about 8, about 12, about 16 or about 24 hours.

[0115] The controlled release formulation may be a sustained release form.The sustained release form may be formulated, for example, to sustain the action of the compound for a long period of time.The sustained release form may be formulated to provide an effective dose of any compound described herein (for example, provide a physiologically effective blood profile) for about 4, about 8, about 12, about 16, or about 24 hours.

[0116] Non-limiting examples of pharma- ceutically acceptable excipients can be found, for example, in Remington: The Science and Practice of Pharmacy, 19th ed. (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania, 1975; Liberman, HA and Lachman, L., eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed. (Lippincott Williams & Wilkins, 1999), each of which is incorporated herein by reference in its entirety.

[0117] The subject can be, for example, an older adult, an adult, an adolescent, a pre-adolescent, a child, a toddler, an infant, a neonate, and a non-human animal. In some embodiments, the subject is a patient.

[0118] The methods disclosed herein relate to administering the compounds disclosed herein as part of a pharmaceutical composition. In some embodiments, the compositions of the compounds disclosed herein can include a liquid that includes an active agent in a solution, a suspension, or both. The liquid composition can include a gel. In some embodiments, the liquid composition is aqueous. Alternatively, the composition can be an ointment. In some embodiments, the composition is an aqueous composition that can gel in situ. In some embodiments, the composition is an aqueous solution that can gel in situ.

[0119] The pharma- ceutically acceptable excipient can be present in the pharmaceutical composition at between about 0.1% and about 99% by weight of the composition. For example, the pharma- ceutically acceptable excipient can be present in the pharmaceutical composition at between about 0.1% and about 95%, between about 0.1% and about 90%, between about 0.1% and about 85%, between about 0.1% and about 80%, between about 0.1% and about 75%, between about 0.1% and about 70%, between about 0.1% and about 65%, between about 0.1% and about 60%, between about 0.1% and about 55%, between about 0.1% and about 100%, between about 0.1% and about 15 ... % to about 50%, between about 0.1% to about 45%, between about 0.1% to about 40%, between about 0.1% to about 35%, between about 0.1% to about 30%, between about 0.1% to about 25%, between about 0.1% to about 20%, between about 0.1% to about 15%, between about 0.1% to about 10%, between about 0.1% to about 5%, or between about 0.1% to about 1% by mass.

[0120] The pharma- ceutically acceptable excipients are about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about ,About 20%,About 21%,About 22%,About 23%,About 24%,About 25%,About 26%,About 27%,About 28%,About 29%,About 30%,About 31%,About 32%,About 33%,About 34%,About 35%,About 36%,About 37%,About 38%,About 39%,About 40%,About 41%,About 42%,About 43%,About 44%,About 45%,About 46%,About 47%,About 48%,About 49%,About 50%,About 51%,About 52%,About 53%,About 54%,About 55%,About 56%,About 57%,About 58%,About 59%,About 60%,About 61%,About 62%,About 63%,About 64%,About 65%,About 66%,About 67%,About 68%,About 69%,About 70%,About 71%,About 72%,About 73%,About 74%,About 75%,About 76%,About 77%,About 78%,About 79%,About 80%,About 81%,About 82%,About 83%,About 84%,About 85%,About 86%,About 87%,About 88%,About 89%,About 90%,About 91%,About 92%,About 93%,About 94%,About 95%,About 96%,About 97%,About 98%,About 99%,About 100%,About 101%,About 102%,About 103%,About 104%,About 105%,About 106%,About 107%,About 108%,About 109%,About 110%,About 111%,About 112%,About 113%,About 114%,About 115%,About 116%,About 117%,About %, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 100%, about 101%, about 102%, about 103%, about 104%, about 105%, about 106%, about 107%, about 108%, about 109%, about 110%, about 111%, about 112%, about 113%, about 114%, about 115%, about 116%, about 117%, about 118%, about 119%, about 120%, about 121%, about 122%, about 123%, about 124%, about 125%, about 126%, about 127%, about 128%, about 129%, about 130%, about 131%, about 132%, about 133%, about 134%, about 135%, about 136%, about 137%, about 138%, about 139%, about 140%, about 141%, about 142%, about 143%, about 144 It can be present at about 3%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, or about 99.9%.

[0121] dosage The pharmaceutical compositions described herein may be in unit dosage form suitable for single administration of precise dosage. In unit dosage form, the formulation is divided into unit doses containing appropriate amounts of one or more compounds. The unit dosage may be in the form of a package containing separate amounts of the formulation. Non-limiting examples are packaged injections, vials, or ampoules. Aqueous suspension compositions may be packaged in single-dose non-reclosable containers. Multi-dose reclosable containers may be used, for example, with or without preservatives. Preparations for parenteral injection may be provided in unit dosage form, for example, in ampoules, and in multi-dose containers with preservatives.

[0122] The compounds described herein may be administered in an amount of about 1 mg to about 5 mg, about 5 mg to about 10 mg, about 10 mg to about 15 mg, about 15 mg to about 20 mg, about 20 mg to about 25 mg, about 25 mg to about 30 mg, about 30 mg to about 35 mg, about 35 mg to about 40 mg, about 40 mg to about 45 mg, about 45 mg to about 50 mg, about 50 mg to about 55 mg, about 55 mg to about 60 mg, about 60 mg to about 65 mg, about 65 mg to about 70 mg, about 70 mg to about 75 mg, about 75 mg to about 80 mg, about 80 mg to about 85 mg, about 85 mg to about 90 mg, about 90 mg to about 95 mg, It may be present in the composition in the range of 95 mg to about 100 mg, about 100 mg to about 125 mg, about 125 mg to about 150 mg, about 150 mg to about 175 mg, about 175 mg to about 200 mg, about 200 mg to about 225 mg, about 225 mg to about 250 mg, about 250 mg to about 300 mg, about 300 mg to about 325 mg, about 325 mg to about 350 mg, about 350 mg to about 375 mg, about 375 mg to about 400 mg, about 400 mg to about 425 mg, about 425 mg to about 450 mg, about 450 mg to about 475 mg, or about 475 mg to about 500 mg.

[0123] The compounds described herein may be present in the composition in an amount of about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 300 about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, or about 500 mg.

[0124] In some embodiments, the compounds described herein may be administered to a subject in an amount of about 0.1 mg / kg to about 500 mg / kg, about 1 mg / kg to about 500 mg / kg, about 0.1 mg / kg to about 300 mg / kg, about 1 mg / kg to about 300 mg / kg, or about 0.1 mg / kg to about 30 mg / kg. In some embodiments, a compound described herein is administered to about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 11 mg / kg, about 12 mg / kg, about 13 mg / kg, about 14 mg / kg, about 15 mg / kg, about 16 mg / kg, about 17 mg / kg, about 18 mg / kg, about 19 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 45 mg / kg, about 50 mg / kg of a subject. In some embodiments, the subject is administered an amount of about 50 mg / kg, about 55 mg / kg, about 60 mg / kg, about 65 mg / kg, about 70 mg / kg, about 75 mg / kg, about 80 mg / kg, about 85 mg / kg, about 90 mg / kg, about 95 mg / kg, about 100 mg / kg, about 120 mg / kg, about 150 mg / kg, about 160 mg / kg, about 180 mg / kg, about 200 mg / kg, about 240 mg / kg, about 250 mg / kg, about 300 mg / kg, about 350 mg / kg, about 360 mg / kg, about 400 mg / kg, about 450 mg / kg, about 500 mg / kg, or about 600 mg / kg.

[0125] Medication Regimen The dosing regimen disclosed herein may be, for example, once a day, twice a day, three times a day, once a week, twice a week, or three times a week. In some embodiments, the compounds disclosed herein are administered once a day. In some embodiments, the compounds disclosed herein are administered once a day for 28 days (one cycle). In some embodiments, the compounds disclosed herein are administered once a day in one or more 28-day cycles. In some embodiments, the compounds disclosed herein are administered in a four-week cycle of three consecutive days of daily administration followed by one week of no administration.

[0126] In some embodiments, the present disclosure provides a method of treating endometrial cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): [ka] A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 Ga-NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof, Administration is once daily for at least 4 weeks; A method is provided.

[0127] In some embodiments, the present disclosure provides a method of treating endometrial cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): [ka] A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 Ga-NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof, The administration is: (i) a consecutive 3-week period of once-daily administration; and ii) a 4-week cycle with a 1-week period without administration immediately following the 3-week period. A method is provided.

[0128] The compounds described herein may be administered before, during, or after the onset of a disease or condition, and the timing of administration of the composition containing the compound may vary. For example, the compounds may be used as prophylactics, and may be administered continuously to subjects with a condition or tendency to a disease to reduce or decrease the likelihood of the onset of the disease or condition. The compounds and compositions may be administered to a subject during the onset of symptoms, or as soon as possible after onset. Administration of the compounds may be initiated within the first 48 hours of the onset of symptoms, within the first 24 hours of the onset of symptoms, within the first 6 hours of the onset of symptoms, or within 3 hours of the onset of symptoms. Initial administration may be by any practical route, for example, by any route described herein, using any formulation described herein.

[0129] The compounds may be administered as soon as is practical after the onset of a disease or condition is detected or suspected, and for the length of time necessary to treat the disease, such as, for example, from about one month to about three months. In some embodiments, the length of time over which the compound may be administered is about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 2 months, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 3 months, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 4 months, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 5 months, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 13 months, about 14 months, about 15 months, about 16 months, about 17 months, about 18 months, about 19 months, about 20 months, about 21 months, about 22 months It can be about 23 months, about 2 years, about 2.5 years, about 3 years, about 3.5 years, about 4 years, about 4.5 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, about 10 years, about 11 years, about 12 years, about 13 years, about 14 years, about 15 years, about 16 years, about 17 years, about 18 years, about 19 years, about 20 years, about 21 years, about 22 years, about 23 years, about 24 years, or about 25 years. The length of treatment can vary from subject to subject.

[0130] The dosing schedule for administering the compound described herein can be consistent with respect to the length of dosing regimen.For example, the compound can be administered every day.Alternatively or in addition, the dosing schedule for administering the compound described herein can include a period of time during which dosing is suspended.For example, the compound can be administered every day for three weeks, and then not administered for one week.

[0131] Dosage schedules for administration of the compounds described herein can include once a day (QD), twice a day (BID), three times a day (TID), four times a day (QID), once a week, twice a week, three times a week, once a month, twice a month, and once every two months.For example, a daily dose can be given in a single dose, or can be divided into multiple doses to be administered at intervals, such as twice a day, three times a day, etc.For example, a daily dose of 100 mg can be given, for example, once a day (100 mg), twice a day (50 mg per dose).

[0132] Multiple therapeutic agents can be administered in any order or simultaneously. In some embodiments, the compound of the present disclosure is administered in combination with, or before or after treatment with, another therapeutic agent, such as a drug, such as an aromatase inhibitor. In some embodiments, the compound of the present disclosure is administered at regular intervals, such as once a day, twice a day, three times a day, and the second therapeutic agent is administered daily or intermittently, or on an as-needed basis. If simultaneously, multiple therapeutic agents can be provided in a single integrated form or in multiple forms, such as multiple separate unit dosage forms. The agents can be packaged together or separately, in a single package or in multiple packages. One or all of the therapeutic agents may be given in multiple doses. If not simultaneously, the timing between multiple doses can vary up to about one month.

[0133] Compound 1 Dosing Regimen Dosage regimens disclosed herein can be, for example, one dose of 40 mg, one dose of 60 mg, one dose of 80 mg, one dose of 120 mg; one dose of 160 mg, or one dose of 200 mg per day of oral 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile. Alternatively, dosing regimens disclosed herein can be, for example, 40 mg twice daily, 60 mg twice daily, 80 mg twice daily, or 100 mg twice daily. In some embodiments, dosing is oral. In some embodiments, the dosing regimen can range from about 200 mg to about 500 mg per day, e.g., about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, or about 500 mg per day.

[0134] Dosing regimens disclosed herein can be, for example, one dose of 40 mg, two doses of 40 mg, three doses of 40 mg, four doses of 40 mg, five doses of 40 mg, six doses of 40 mg, seven doses of 40 mg, eight doses of 40 mg, nine doses of 40 mg, ten doses of 40 mg, eleven doses of 40 mg, or twelve doses of 40 mg of oral 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile per day. In some embodiments, dosing is oral.

[0135] Dosing regimens disclosed herein can be, for example, one dose of 60 mg, two doses of 60 mg, three doses of 60 mg, four doses of 60 mg, five doses of 60 mg, six doses of 60 mg, seven doses of 60 mg, eight doses of 60 mg, oral 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile per day. In some embodiments, dosing is oral.

[0136] In some embodiments, 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile is administered once a day. In some embodiments, 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile is administered once a day for 28 days (one cycle). In some embodiments, 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile is administered once a day in one or more 28-day cycles. In some embodiments, 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile is administered in a 4 week cycle of once daily dosing for 3 consecutive weeks followed by 1 week of no dosing.

[0137] In some embodiments, the disclosure provides a method of treating hormone receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, wherein the administering is once daily for at least four weeks.

[0138] In some embodiments, the disclosure provides a method of treating hormone receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle of one week of no administration immediately following the three week period.

[0139] In some embodiments, the disclosure provides a method of treating hormone receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, wherein the administering is once daily for at least four weeks.

[0140] In some embodiments, the disclosure provides a method of treating hormone receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0141] In some embodiments, the disclosure provides a method of treating progesterone receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, wherein the administering is once daily for at least four weeks.

[0142] In some embodiments, the disclosure provides a method of treating progesterone receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0143] In some embodiments, the disclosure provides a method of treating progesterone receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, wherein the administering is once daily for at least four weeks.

[0144] In some embodiments, the disclosure provides a method of treating progesterone receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0145] In some embodiments, the disclosure provides a method of treating estrogen receptor-positive, progesterone receptor-positive endometrial cancer in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, wherein the administering is once daily for at least four weeks.

[0146] In some embodiments, the disclosure provides a method of treating estrogen receptor-positive, progesterone receptor-positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0147] In some embodiments, the disclosure provides a method of treating estrogen receptor positive, progesterone receptor positive endometrial cancer in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, wherein the administering is once daily for at least four weeks.

[0148] In some embodiments, the disclosure provides a method of treating estrogen receptor-positive, progesterone receptor-positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0149] In some embodiments, the disclosure provides a method of treating estrogen receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, wherein the administering is once daily for at least four weeks.

[0150] In some embodiments, the disclosure provides a method of treating estrogen receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0151] In some embodiments, the disclosure provides a method of treating estrogen receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, wherein the administering is once daily for at least four weeks.

[0152] In some embodiments, the disclosure provides a method of treating estrogen receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0153] In some embodiments, the disclosure provides a method of treating recurrent metastatic low-grade endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, wherein the administering is once daily for at least four weeks.

[0154] In some embodiments, the disclosure provides a method of treating recurrent metastatic low-grade endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle of one week of no administration immediately following the three week period.

[0155] In some embodiments, the disclosure provides a method of treating recurrent metastatic low-grade endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, wherein the administering is once daily for at least four weeks.

[0156] In some embodiments, the disclosure provides a method of treating recurrent metastatic low-grade endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0157] Letrozole Dosing Regimen The dosing regimen disclosed herein can be, for example, once a day, twice a day, three times a day, once a week, twice a week, or three times a week. In some embodiments, dosing is oral. In some embodiments, a suitable amount of letrozole can range from about 0.1 mg to about 100 mg per day, for example, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 2 mg, about 2.5 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 ...9 mg, about 49 mg, about 49 mg About 3mg, about 3.5mg, about 4mg, about 4.5mg, about 5mg, about 6mg, about 7mg, about 8mg, about 9mg, about 10mg, about 11mg, about 12mg, about 13mg, about 1 4mg, about 15mg, about 16mg, about 17mg, about 18mg, about 19mg, about 20mg, about 21mg, about 22mg, about 23mg, about 24mg, about 25mg, about 26mg, It can be about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 46 mg, about 47 mg, about 48 mg, about 49 mg, or about 50 mg.

[0158] Compound 1 and Letrozole Dosing Regimen The dosing regimen disclosed herein can be, for example, a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and letrozole. In some embodiments, the dosing is oral. In some embodiments, a suitable amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile can range from about 40 mg to about 500 mg per day, for example, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 40 ... 50mg, about 160mg, about 170mg, about 180mg, about 190mg, about 200mg, about 210mg, about 220mg, about 230mg, about 240mg, about 250mg, about 260mg, about 270mg, about 280mg, about 290mg, about 300mg, about 310mg, about 320mg, about 330mg, about 340mg, about 350mg, about 360mg, about 370mg, about 380mg, about The preferred amount of letrozole may range from about 0.1 mg to 20 mg per day, for example, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 21 mg, about 22 mg, about 23 mg, about 24 mg, about 25 mg, about 26 mg, about 27 mg, about 28 mg, about 29 mg, about 30 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, and a preferred amount of letrozole may range from about 0.1 mg to 20 mg per day, for example, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.8 mg, about 0.9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 25 mg, about 26 mg, about 27 mg g, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, or about 20 mg.

[0159] In some embodiments, the combination can be, for example, 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and 2.5 mg of letrozole administered once daily. In some embodiments, the combination can be, for example, 60 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and 2.5 mg of letrozole administered once daily. In some embodiments, the combination can be, for example, 80 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and 2.5 mg of letrozole administered once daily. In some embodiments, the combination can be, for example, 120 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and 2.5 mg of letrozole administered once daily. In some embodiments, the combination can be, for example, 160 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and 2.5 mg of letrozole administered once daily. In some embodiments, the combination can be, for example, 200 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and 2.5 mg of letrozole administered once daily. In some embodiments, the combination can be, for example, 240 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and 2.5 mg of letrozole administered once daily.In some embodiments, the combination can be, for example, 280 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and 2.5 mg of letrozole administered once daily. In some embodiments, the combination can be, for example, 320 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and 2.5 mg of letrozole administered once daily. In some embodiments, the combination can be, for example, 360 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and 2.5 mg of letrozole administered once daily. In some embodiments, the combination can be, for example, 400 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and 2.5 mg of letrozole administered once daily. In some embodiments, the combination can be, for example, 440 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and 2.5 mg of letrozole administered once daily. In some embodiments, the combination can be, for example, 480 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and 2.5 mg of letrozole administered once daily.

[0160] In some embodiments, the combination is administered once a day. In some embodiments, the combination is administered once a day for 28 days (one cycle). In some embodiments, the combination is administered once a day in one or more 28-day cycles. In some embodiments, the combination is administered in a four-week cycle of three consecutive days of daily administration followed by one week of no administration.

[0161] In some embodiments, the combination is administered once a day. In some embodiments, the combination is administered once a day for 28 days (one cycle). In some embodiments, the combination is administered once a day in one or more 28-day cycles. In some embodiments, the combination is administered in a four-week cycle of three consecutive days of daily administration followed by one week of no administration.

[0162] In some embodiments, the disclosure provides a method of treating hormone receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is once daily for at least four weeks.

[0163] In some embodiments, the disclosure provides a method of treating hormone receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0164] In some embodiments, the disclosure provides a method of treating progesterone receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is once daily for at least four weeks.

[0165] In some embodiments, the disclosure provides a method of treating progesterone receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0166] In some embodiments, the disclosure provides a method of treating estrogen receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is once daily for at least four weeks.

[0167] In some embodiments, the disclosure provides a method of treating estrogen receptor positive endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0168] In some embodiments, the disclosure provides a method of treating recurrent metastatic low-grade endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is once daily for at least four weeks.

[0169] In some embodiments, the disclosure provides a method of treating recurrent metastatic low-grade endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0170] In some embodiments, the disclosure provides a method of treating a subject having a disease caused by a mutation, e.g., a POLE mutation, comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is once daily for at least four weeks.

[0171] In some embodiments, the disclosure provides a method of treating a subject having a disease caused by a mutation, e.g., a POLE mutation, comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0172] In some embodiments, the disclosure provides a method of treating a subject having a disease caused by mismatch repair deficiency (DMMR), comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is once daily for at least four weeks.

[0173] In some embodiments, the disclosure provides a method of treating a subject having a disease caused by mismatch repair deficiency (DMMR), comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0174] In some embodiments, the disclosure provides a method of treating a subject having a disease caused by microsatellite instability (MSI), comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is once daily for at least four weeks.

[0175] In some embodiments, the disclosure provides a method of treating a subject having a disease caused by microsatellite instability (MSI), comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period.

[0176] In some embodiments, the disclosure provides a method of treating a subject having a disease caused by alteration of p53 tumor suppressor activity, comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is once daily for at least four weeks.

[0177] In some embodiments, the disclosure provides a method of treating a subject having a disease caused by alteration of p53 tumor suppressor activity, comprising administering to the subject a therapeutically effective amount of a combination of 8-cyclopentyl-2-((4-(4-methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and letrozole, wherein the administering is (i) once daily administration for three consecutive weeks, and ii) a four week cycle with one week of no administration immediately following the three week period. EXAMPLES

[0178] Example 1 A study to evaluate the oral pharmaceutical compositions disclosed herein for treating a disease in a subject. Summary: This is a dose escalation study to investigate the safety, tolerability and PK characteristics of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile (Compound 1) in patients with advanced cancer who have received and failed at least one prior treatment. The primary goal of this study is to evaluate the safety and tolerability of repeated daily dosing of Compound 1 in patients with relapsed and / or refractory advanced cancer. The secondary goal of this study is to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of orally administered Compound 1. Additionally, this study will explore the efficacy of Compound 1 in cancer patients.

[0179] Study Design: This study is a dose-finding study using a 3+3 design for dose escalation. Three to six patients will be enrolled per dose cohort, followed by up to 12 additional patients at the RP2D. Based on the four dose levels and escalation cohorts, approximately 36 patients with advanced cancer will be enrolled in the study. If additional dose escalation is required to establish the MTD / RP2D, 3 to 6 additional patients will be added per dose level.

[0180] Compound (1) is given in the form of a hard capsule containing 48.4 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, equivalent to 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile. The initial dose is 40 mg (one capsule) taken once daily for 28 days (one cycle). The dose is taken in the morning on an empty stomach. The dose increment in the dose escalation 3+3 study is 40 mg of Compound 1 per cycle. Dose levels are 40mg, 80mg, 120mg, 160mg, etc. until the RP2D / MTD is reached. Each of the first three patients in the first and subsequent cohorts is evaluated for dose-limiting toxicity (DLT) during the first 28 days of treatment. If no patient experiences a DLT, enrollment into the next cohort begins at the next dose level. If one patient out of the first three patients in a cohort experiences a DLT during the first 28 days, three additional patients are enrolled in that cohort for a total of six patients. If only one out of six patients in a cohort experiences a DLT during the first 28 days, enrollment into the next cohort begins at the next dose level. Whenever two or more patients in a cohort experience a DLT during the first 28 days, the cohort is closed. The dose of that cohort is deemed "unacceptable" and the previous dose level is defined as the MTD. Patients continue in the study until disease progression or intolerance or a decision to discontinue is reached.

[0181] Study Objectives and Endpoints

[0182] The primary goal of this study is to evaluate the safety and tolerability of repeated daily dosing of Compound 1 in patients with relapsed and / or refractory advanced cancer. Primary endpoints include (DLTs, adverse events (AEs), deaths and other serious AEs.

[0183] Secondary objectives of this study are to establish the MTD of Compound 1 and the RP2D of orally administered Compound 1 in patients with relapsed and / or refractory advanced cancer and to characterize the pharmacokinetics of Compound 1 following oral administration. Secondary endpoints include maximum plasma concentration (Cmax), area under the plasma concentration-time curve (AUC) and half-life (t1 / 2).

[0184] The exploratory goal of this study is to evaluate the efficacy of Compound 1 by objective response according to RECIST, whenever appropriate for applicable tumors. Evaluation of non-Hodgkin's lymphoma and CNS tumors will be by imaging techniques (CT, PET, MRI).

[0185] Pharmacokinetics

[0186] Blood samples are collected for pharmacokinetic (PK) analysis pre- and post-dose on days 1 and 8 of cycle 1, and pre-dose on days 1 of cycles 2 and 3. Compound (1) concentrations are determined in plasma samples by a validated liquid chromatography-tandem mass spectrometry (LC-MS / MS) assay. Compound 1 levels are determined at the designated time points in the PK profile.

[0187] The following PK parameters are derived using model-independent analysis: time to reach Cmax (Tmax), Cmax, t 1 / 2 , AUC0-t, AUC0-α, CL, and Vss. Descriptive statistics (mean, median, range, standard deviation) of these parameters are provided and summarized by each dose group.

[0188] Cmax and Tmax are determined from the plasma concentration-time profile, and t1 / 2β is calculated as 0.693 / k, where k is the terminal elimination rate constant calculated by log-linear regression of the terminal portion of the concentration-time profile. AUC0-t is calculated by the linear trapezoidal rule and extrapolated to infinity using k to obtain AUC0-∞.

[0189] Pharmacokinetic parameters are calculated from Compound 1 concentration-time data using standard non-compartmental methods implemented in WinNonlin. Maximum plasma concentration (Cmax) and time to reach Cmax (Tmax) are observed values. Area under the plasma concentration-time curve (AUC) values ​​are calculated to the last quantifiable sample (AUClast) by use of the linear trapezoidal rule. AUC values ​​are extrapolated to infinity (AUCinf) by dividing the last quantifiable concentration by the terminal disposition rate constant (λz) determined from the slope of the terminal phase of the concentration-time profile. Terminal half-life (T1 / 2) is calculated as 0.693 divided by λz. Apparent oral clearance (Cl / F) is calculated by dividing the administered dose by AUCinf.4. Pharmacokinetic data are analyzed by cohort.

[0190] Efficacy Analysis. The efficacy variable is best overall response (ORR) using RECIST criteria, version 1.1. Objective tumor responses will be tabulated and summarized by primary tumor type. If warranted, additional efficacy endpoints such as duration of response or time to progression will be analyzed.

[0191] Example 2 Studies to evaluate the PK / PD outcomes of the pharmaceutical compositions disclosed herein for treating diseases in subjects Summary: This is a dose escalation study to investigate the safety, tolerability and PK characteristics in in-patients with advanced solid tumors who have received and failed at least one prior treatment. The primary goal of this study is to evaluate the safety and tolerability of repeated daily dosing of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile (Compound 1) in patients with recurrent and / or refractory advanced cancer. Secondary goals of this study are to establish the MT of Compound 1 and the RP2D of orally administered Compound 1. In addition, this study will explore the efficacy of Compound 1 in cancer patients.

[0192] Study Design: The study includes a treatment period (1 year) and a follow-up period (90 days after the last dose). Subjects have pathologically confirmed malignant solid tumors or progressive (metastatic or unresectable) malignant solid tumors and have previously failed standard treatments (e.g., targeted therapy, chemotherapy, biotherapy, immunotherapy, etc.) as evidenced by disease progression or intolerable toxicity. Subjects may be included in the study if there is currently no effective treatment for cancer.

[0193] The study is divided into two stages including dose escalation and dose expansion cohorts. The first phase is dose escalation using a 3+3 design to determine the MTD and / or RP2D. Three to six patients will be enrolled per dose cohort, followed by up to 12 additional patients at the RP2D. Approximately 9-30 patients will be enrolled in the first phase. If additional dose escalation is required to establish the MTD / RP2D, 3-6 additional patients will be added per dose level.

[0194] Patients will receive study drug orally under fasting conditions before breakfast. Compound (1) will be administered once daily for three consecutive weeks, followed by one week of withdrawal. Safety, tolerability and dose-limiting toxicity will be evaluated after four weeks (28 days) of dosing.

[0195] Compound (1) is given in the form of a hard capsule containing 48.4 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, equivalent to 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile. The dose (one capsule) is taken in the morning on an empty stomach. The dose increment in the dose escalation 3+3 study is 40 mg of Compound 1 per cycle. The dose levels are 40 mg, 80 mg, 120 mg, 160 mg, and 200 mg, or until the RP2D / MTD is reached. The maximum escalating dose in this study is set at 200 mg. Dose escalation will be performed as described in Example 1.

[0196] The second stage of this study is the dose escalation stage. The dose escalation stage will enroll 9 to 12 cancer patients (mainly advanced breast cancer and non-small cell lung cancer patients, HR(+) and HER2(-)). The study procedures will be the same as those in the dose escalation phase.

[0197] Study Objectives and Endpoints

[0198] The primary goal of this study is to evaluate the tolerability, safety, and antitumor efficacy of Compound 1 in patients with advanced solid tumors.

[0199] The secondary objective of this study is to characterize the pharmacokinetics of Compound 1 following single and multiple dose oral administration of Compound 1 in patients with recurrent and / or refractory advanced cancer. Secondary endpoints include maximum plasma concentration (Cmax), area under the plasma concentration-time curve (AUC) and half-life (t1 / 2). This study will evaluate the efficacy of Compound 1 in patients with solid tumors, including objective response rate (ORR), progression-free survival (PFS), duration of remission (DOR), disease control rate (DCR), etc.

[0200] Pharmacokinetics

[0201] Blood samples are collected for pharmacokinetic (PK) analysis pre- and post-dose on days 1 and 8 of the first cycle, and pre-dose on day 4 of the first cycle. Compound (1) PK is determined as described in Example 1. Efficacy Analyses. The efficacy variable for this study was best overall response (ORR) using RECIST criteria, version 1.1. Efficacy analyses included: (1) objective remission rate (ORR), defined as the proportion of subjects with complete response (CR) and partial response (PR) after treatment; (2) disease control rate (DCR), defined as the proportion of subjects with complete response (CR), partial response (PR), and disease stabilization (SD) after treatment; (3) time to remission (DOR), defined as the time from first documentation of objective remission to first appearance of tumor progression or death from any cause; and (4) progression-free survival (PFS), defined as the time from start of treatment to tumor progression or death from any cause.

[0202] Example 3 Dosing regimens for evaluating the oral pharmaceutical compositions and aromatase inhibitors disclosed herein in subjects This study is a randomized, double-blind, placebo-controlled study of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile (Compound 1) in combination with an aromatase inhibitor (e.g., letrozole) versus placebo in combination with an aromatase inhibitor (e.g., letrozole) for patients with estrogen receptor-positive advanced or recurrent endometrial cancer.

[0203] Study Design: This is a treatment response study using a 1:1 randomized double-blind design. Patients will be randomized into one of two treatment arms: Arm A (placebo): letrozole-placebo combination therapy; and Arm B (experimental): letrozole-compound 1 combination therapy. Each cycle in this study is 28 days of treatment and tumors will be evaluated every 12 weeks.

[0204] Compound (1) is given in the form of a hard capsule containing 48.4 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, equivalent to 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile. Compound (1) is taken once daily for 28 days (one cycle). Alternatively, Compound 1 is taken once daily for three consecutive weeks, with one week off, for a total of 28 days. Treatment continues until disease progression or unacceptable toxicity. Compound (1) is taken in the morning on an empty stomach.

[0205] Letrozole is given in the form of 2.5 mg tablets. One 2.5 mg letrozole tablet is taken once on days 1-28 (one cycle). Treatment continues until disease progression or unacceptable toxicity. Letrozole is taken in the morning, concurrently with either Compound 1 or placebo.

[0206] Primary Outcome Measure The primary outcome measure is the increase in progression-free survival (PFS) in the experimental arm versus the comparator arm.

[0207] Secondary outcome measures were: 1. PFS: Increase in median PFS in the experimental arm versus the comparator arm. 2. Overall response rate (ORR) according to RECIST. 3.Disease control rate (DCR) for at least 12 weeks. 4. Time to first subsequent treatment (TFST): time from randomization to first subsequent treatment or death. 5. Progression Free Survival 2 (PFS2): The time from randomization to second objective disease progression or death. 6. Time to second subsequent treatment (TSST): time from randomization to second subsequent treatment or death. 7. Patient-reported outcomes (PROs) such as the Quality of Life questionnaires EORTC-QLQ-C30 & EORTC-QLQ-EN24. These are validated questionnaires to be answered by the patient. Results are reported narratively and on a scale of 1 to 10. 8. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0. 9. Compliance in the two treatment arms. 10. Dose reduction / interruption in both treatment arms.

[0208] The toxicity / efficacy of various compounds of the present disclosure are analyzed and compared.

[0209] Example 4 Dosing regimens for evaluating the oral pharmaceutical compositions and progestins disclosed herein in subjects This study is a randomized, double-blind, placebo-controlled study of 8-cyclopentyl(cyclopenty1)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile (Compound 1) in combination with a progestin (e.g., megestrol acetate) versus placebo in combination with a progestin (e.g., megestrol acetate) for patients with estrogens.

[0210] Study Design: This is a treatment response study using a 1:1 randomized double-blind design. Patients will be randomized into one of two treatment arms: Arm A (placebo): megestrol acetate-placebo combination; and Arm B (experimental): megestrol acetate-Compound 1 combination. Each cycle in this study is 28 days of treatment, and tumors will be evaluated every 12 weeks.

[0211] Compound (1) is given in the form of a hard capsule containing 48.4 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, equivalent to 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile. Compound (1) is taken once daily for 28 days (one cycle). Alternatively, Compound 1 is taken once daily for three consecutive weeks, with one week off, for a total of 28 days. Treatment continues until disease progression or unacceptable toxicity. Compound (1) is taken in the morning on an empty stomach.

[0212] Megestrol acetate is given in the form of an oral suspension of 625 mg per day (5 mL of a 125 mg / mL suspension per day or one teaspoon daily). One 625 mg megestrol acetate dose is taken once on days 1-28 (one cycle). Treatment continues until disease progression or unacceptable toxicity. Megestrol acetate is taken in the morning, concurrently with either Compound 1 or placebo.

[0213] Primary Outcome Measure The primary outcome measure is the increase in progression-free survival (PFS) in the experimental arm versus the comparator arm.

[0214] Secondary outcome measures were: 1. PFS: Increase in median PFS in the experimental arm versus the comparator arm. 2. Overall response rate (ORR) according to RECIST. 3.Disease control rate (DCR) for at least 12 weeks. 4. Time to first subsequent treatment (TFST): time from randomization to first subsequent treatment or death. 5. Progression Free Survival 2 (PFS2): The time from randomization to second objective disease progression or death. 6. Time to second subsequent treatment (TSST): time from randomization to second subsequent treatment or death. 7. Patient-reported outcomes (PROs) such as quality of life questionnaires EORTC-QLQ-C30 & EORTC-QLQ-EN24. These outcomes are validated questionnaires to be answered by the patient. Results are reported narratively and on a scale of 1 to 10. 8. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0. 9. Compliance in the two treatment arms. 10. Dose reduction / interruption in both treatment arms.

[0215] The toxicity / efficacy of various compounds of the present disclosure are analyzed and compared.

[0216] Example 5 In vitro multikinase activity - IC 50 value This study compares the IC of compound 1 with FDA-approved CDK4 / 6 inhibitors comparator 1, comparator 2, and comparator 3, representing a treatment advance for HR+ HER2- metastatic breast cancer. 50 Evaluate the IC value (in nM). 50 The values ​​are a quantitative measure of the concentration required for 50% inhibition of the listed kinases. The results are shown in Table 1. [Table 1]

[0217] Table 1 shows that Compound 1 has comparable IC for CDK4 and CDK6 as Control 1, Control 2, and Control 3.50 Compound 1 had significantly lower IC values ​​for CSF1R, ARK5, and KIT than Control 1, Control 2, and Control 3. 50 Compound 1 had significantly lower IC values ​​(1-3 orders of magnitude lower) for CDK1, CDK2, CDK7, CDK9, CDK16, and CDK17 than Control 1 and Control 2. 50 values ​​(1-3 orders of magnitude lower). This study demonstrates that compound 1 is highly effective in inhibiting multiple kinases.

[0218] Example 6 Dosing regimens for evaluating the oral pharmaceutical compositions disclosed herein in subjects This is a Phase 1 dose escalation study of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile (Compound 1) in patients with advanced cancer. Patients receive Compound 1 daily in a 28-day cycle or only on days 1-21 of a 28-day cycle, with dosage escalation in 40 mg / day increments starting with 40 mg daily with each new cohort. No dose-limiting toxicities were observed with the 200 mg / day cohort. Adverse events reported were grade 1 or 2 in severity, primarily gastrointestinal (GI) disorders.

[0219] Example 7 Dosing regimens for evaluating oral pharmaceutical compositions disclosed herein in combination with aromatase inhibitors in subjects This is an open-label, multicenter study of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile (Compound 1) in combination with an aromatase inhibitor (e.g., letrozole) for patients with endometrial cancer.

[0220] Study Design: This is a Phase 1 / 2a, open-label, multicenter study to evaluate the safety and efficacy of escalating doses of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile (Compound 1) in combination with oral letrozole once daily. Approximately 30 patients with endometrial cancer will be enrolled in the Phase 1 study. The primary goal of the Phase 1 study is to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of escalating doses of Compound 1 administered orally once daily in combination with oral letrozole 2.5 mg once daily and to determine the recommended Phase 2 dose (RP2D). Dose escalation will follow a standard 3+3 design. Approximately 20 patients with endometrial cancer will be enrolled in the Phase 2a study. Treatment will continue until disease progression, patient withdrawal, or unacceptable drug-related toxicity. The primary objective of the Phase 2a study is to investigate the efficacy of Compound 1 administered orally once daily in combination with letrozole 2.5 mg orally once daily, as measured by a metric of progression-free survival (PFS) at 24 weeks as determined by investigator assessment.

[0221] Compound 1 was prepared by dissolving 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, equivalent to 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile. It is given in the form of a transparent hard capsule containing 40 mg or 60 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, which is equivalent to 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate. The starting dose of compound 1 is 200 mg taken once a day for a 28-day treatment cycle (1 cycle) in a 3+3 design. After one treatment cycle, the dose of Compound 1 is titrated in increments of 40 mg / day, and new cohorts are enrolled at the increased dosage (e.g., 240 mg taken once a day for the treatment cycle), while previous cohorts are allowed to titrate to the titrated dose. Treatment continues until the minimum effective biological dose (MBED) or maximum tolerated dose (MTD) is reached, and the RP2D is determined. In phase 2a studies, Compound 1 is given at the RP2D obtained from phase 1. Compound 1 is taken in the morning on an empty stomach with water, at least 1 hour before starting breakfast.

[0222] Compound 1 dose modifications and management guidelines will depend on adverse events of particular interest (AESIs). Dose reductions will not be permitted during the first 28 days in any of the dose escalation cohorts, but will be permitted thereafter. Any request for dose modification below 200 mg / day of Compound 1 will result in withdrawal from the study. Dose escalation will occur after a cohort has completed 28 days of dosing with no dose-limiting toxicity observed (n=3) or with no more than one patient experiencing dose-limiting toxicity (n=6).

[0223] Dose Modifications for Neutropenia: Complete blood counts will be monitored if clinically indicated prior to initiation of Compound 1 dosing. Dose modifications will depend on the Common Terminology Criteria for Adverse Events (CTCAE grades): i. CTCAE Grade 1 or 2: No dose modification of Compound 1 is required ii. CTCAE Grade 3: Dose withheld until toxicity resolves to Grade 2 or less; no dose reduction required iii.CTCAE Grade 3 recurrent: Withhold dose until toxicity resolves to Grade 2 or less, then resume at next lower dose iv. CTCAE Grade 4: Discontinue Compound 1

[0224] Letrozole is given in the form of 2.5 mg tablets. One 2.5 mg letrozole tablet is taken once on days 1-28 (one cycle). Treatment continues until disease progression or unacceptable toxicity. Letrozole is taken simultaneously with Compound 1 in the morning.

[0225] Phase 1 Primary Outcome Measures: The primary outcome measures are safety, tolerability, PK, and PD of escalating doses of Compound 1 administered orally once daily in combination with letrozole 2.5 mg orally once daily.

[0226] Phase 2a Primary Outcome Measures: The primary outcome measure is efficacy of Compound 1 administered orally once daily at the RP2D in combination with letrozole 2.5 mg orally once daily, as measured by PFS at 24 weeks.

[0227] Phase 1 secondary outcome measures are the MBED and / or MTD of Compound 1 administered orally once daily in combination with letrozole 2.5 mg orally once daily, and the RP2D.

[0228] Phase 1 and 2a secondary outcome measures are the following efficacy endpoints at weeks 16 and 24, assessed by using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1: 1. Investigator-assessed PFS at 16 weeks 2.Median PFS as assessed by investigator 3. Complete response (CR) rate 4.Partial response (PR) rate 5. Stable disease (SD) rate 6. Overall response rate (ORR equals CR+PR) 7.Disease control rate (DCR is equal to CR+PR+SD) 8. Duration of Response (DoR) 9. Time to Response (TTR) 10. Overall survival (OS) Furthermore, secondary outcome measures of the Phase 1 and Phase 2a trials are to evaluate the safety and tolerability of the RP2D of Compound 1 in combination with letrozole 2.5 mg orally once daily.

[0229] Phase 1 and 2a exploratory measures are: 1. Estrogen / Progesterone Receptor Status 2.RB Status 3. CCNE1 / CCND1 expression in tissues 4. CCNE1 / CCND1 expression in ctDNA 5.POLE molecular classification 6.DMMR molecular classification 7.MSI Molecular Classification 8.P53 Molecular classification 9. PK parameters including: i. Maximum plasma concentration of the drug [C max ] ii.C max Time to reach (T max ) iii. Terminal half-life [T 1 / 2 ] iv. Area under the concentration-time curve [AUC] from time 0 to the time of the last quantifiable sample [AUC 0-t ] v. AUC extrapolated to infinity [AUC 0-∞ ], vi. Clearance [CL] vii. Volume of distribution at steady state [Vss] 10.PD rating.

[0230] Pharmacokinetic Measurements: Pharmacokinetic (PK) samples will be collected from all patients on days 1 and 8 of the first 28-day cycle. PK samples will be collected pre-dose on both days, then 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose. 24-hour samples will be collected prior to dosing on days 2 and 9 of the 28-day cycle, and a single pre-dose PK sample will be collected on day 1 of cycles 2 and 3.

[0231] Pharmacodynamics assessment: Pharmacodynamics (PD) samples for serum TK1 activity levels will be collected at screening, pre-dose on days 1, 8, 15, 22 of dose cycle 1, then pre-dose on day 1 of all dose cycles, and at the end of study (EOT). The efficacy of compound 1-letrozole combination treatment will be assessed using validated DiviTum® TKa technology. PD parameters will be calculated based on the change in serum TKa levels using serial measurements before and during treatment, and the relationship between TKa, drug PK, and patient response to compound 1-letrozole combination treatment will be analyzed for each time point, each dosing cohort, and each specific diagnosis / tumor type. Descriptive statistics for each parameter will be provided and summarized by each dose group.

[0232] Inclusion Criteria Patients met the following criteria for inclusion in this study: 1. Be 18 years of age or of legal age of consent in the jurisdiction of the study at the time of signing the informed consent form 2. Have recurrent metastatic or progressive (Stage IV) disease 3. Have received 1 or 2 prior lines of systemic therapy for metastatic disease 4. Have not received 3 or more prior lines of systemic therapy for endometrial cancer, including checkpoint inhibitors, hormonal therapy, or chemotherapy. Prior external beam radiation therapy, brachytherapy, and / or surgery for localized disease is permitted and does not count as a line of treatment. 5. Have measurable disease outside the radiation field 6. Have local mismatch repair (MMR) immunohistochemistry results available; dMMR and MMRp patients are eligible and will be of record for research purposes Have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 7.0 or 1 8. Have tissue available for estrogen / progesterone receptor status and molecular typing analysis. 9.Has adequate organ function as demonstrated by: Absolute neutrophil count (ANC) ≥ 1.0 x 10 9 / L b. Platelets ≧100×10 9 / L C. Hemoglobin ≥ 9.0 g / dL d. International normalized ratio (INR) ≦ 1.5 Creatinine clearance estimated by the Cockcroft-Gault formula ≥ 60 / mL f. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) below 3.0 × upper limit of normal (ULN) (or ALT and AST ≤ 5 × ULN if liver metastases are present). g. Total serum bilirubin < 1.5 × ULN; or total bilirubin ≤ 3.0 × ULN and direct bilirubin within the central laboratory normal range in participants with well-documented Gilbert syndrome. 10. Have a baseline QTc interval <470 ms. 11. Able to swallow oral medications. 12. Have a life expectancy of at least 12 weeks 13. Sexual Intercourse and Contraception / Barrier Requirements A. Postmenopausal, defined as: i. The patient's last menstrual period occurred more than 12 months prior to screening, without any alternative medical cause; and ii. The patient's postmenopausal status is confirmed by a screening serum follicle-stimulating hormone concentration of >40 mIU / mL; or iii. The patient has undergone surgical sterilization (bilateral oophorectomy and / or hysterectomy). or b. If not postmenopausal, must have a negative pregnancy test at screening and at the time of study entry (Day 1 of Cycle 1); and c. For participants in clinical studies who are not postmenopausal, contraceptive use must be consistent with local regulations regarding contraceptive methods. Patients under 55 years of age with intact ovaries will undergo hormonal validation. 14.Able to provide signed informed consent, including compliance with the requirements and restrictions contained in the ICF and this protocol.

[0233] Exclusion Criteria: Patients will be excluded from the study if they exhibit any of the following: 1.Having previously received a CDK4 / 6 inhibitor 2. Has any significant medical condition, laboratory abnormality, or psychiatric illness that, in the opinion of the Investigator, would prevent the patient from participating in the study or would present an unacceptable risk to the patient. 3. At risk for polymorphic ventricular tachycardia (TdP): Patients who have significant baseline prolongation of the QT / QTc interval using the Fredericia QT correction formula (e.g., repeated demonstration of QTc interval >470 ms) or have a history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of long QT syndrome) or are currently taking medications that prolong the QT / QTc interval. 4. Has any uncontrolled intercurrent or significant medical illness, serious underlying medical condition, abnormal laboratory finding, or psychiatric illness / social situation that, in the judgment of the Investigator or Sponsor, may prevent the participant from receiving study treatment or being followed in the study or may otherwise make the participant unsuitable for the study, including, but not limited to, ongoing or active infection, bleeding, congestive heart failure, unstable angina, cardiac arrhythmias, oxygen-dependent pulmonary disease, and psychiatric illness / social situation that limits participation in and compliance with study procedures and requirements. 5. Currently taking, or within 5 half-lives of taking, strong inducers and inhibitors of cytochrome P450 enzymes (CYP) 2C8 and CYP3A4. 6. Have a recent history of a venous thromboembolic event defined as an event occurring <6 months prior to screening and currently being treated, known underlying hypercoagulability, or a major thromboembolic event within the past 2 years. 7. Have baseline grade ≥2 diarrhea. 8.Have grade ≥ 3 hypercalcemia (corrected serum calcium > 12.5 mg / dL). 9. Pregnant or breastfeeding. 10. Have had major surgery within 14 days prior to screening to allow for post-operative healing of surgical wound and site(s). 11. Recent (within 28 days prior to screening) exposure to a live attenuated vaccine. 12. Have an active infection, including bacterial or fungal infection or active viral infection or viral load, including any human immunodeficiency virus (HIV) or Hepatitis B (HBV) virus, Hepatitis C virus (HCV), or SARS-CoV-2 (COVID-19). 13. Currently have or have been treated within the past 2 years for any other cancer or malignant disease, except for: Non-melanoma skin cancer, including basal cell carcinoma of the skin b.Cervical intraepithelial neoplasia curatively treated. 14.Has any clinically significant uncontrolled cardiac disease and / or cardiac repolarization abnormality. Has a history of any of the following: A. Syncope of cardiovascular etiology B. Ventricular arrhythmias of pathological origin c. Sudden cardiac arrest d. Documented history of congestive heart failure with reduced ejection fraction. 15.Has interstitial pneumonia or severe impairment of pulmonary function defined as: A vital capacity and diffusing capacity of the lungs for carbon monoxide (DLCO) of ≤ 50% of normal predicted values, or b. Resting oxygen (O2) saturation in the ambient environment of ≤88%. 16. Has received, is currently receiving, or intends to receive during the study, any non-investigational anti-cancer treatment within 21 days prior to screening, including but not limited to any of the following: Anticancer drugs b. Investigational drugs c. Surgical intervention d. Radiation intervention, including any radiation therapy (including radiation to isolated lesions) (symptomatic radiation to non-target lesions is acceptable). 17. Have central nervous system metastasis or meningeal carcinomatosis. 18. Not a candidate for treatment with letrozole.

[0234] Phase 1 and 2a Schedule of Evaluation: Phase 1 and 2a clinical trials will proceed according to the following schedule: i. Informed consent is obtained on days -28 to -1 prior to the start of the first dose cycle. ii. Participant medical history and study eligibility screening Demographics on Days -28 to -1 prior to the start of the first dose cycle b. Inclusion / exclusion criteria on days -28 to -1 and -7 to -1 prior to the start of the first dose cycle, and on day 1 of the first dose cycle c. Treatment history and current medical condition from Day -28 to Day -1 prior to the start of the first dose cycle. d. Tumor histology on days -28 to -1 prior to the start of the first dose cycle e. Diagnosis and extent of cancer on days -28 to -1 prior to the start of the first dose cycle. f. Prior antineoplastic therapy on days -28 to -1 prior to the start of the first dose cycle g. Prior and concomitant medications beginning within 15 days after the last dose from day -28 through day -1, and throughout the duration of the treatment cycle until the end of the study or end of dosing. iii. Physical Examination a. Physical examination, including a complete physical examination beginning on days -7 to -1 prior to the start of the first dose cycle, and on day 1 of each subsequent dose cycle, and at the end of the study or end of dosing, within 15 days after the last dose b. ECOG PS on days -7 to -1 prior to the start of the first dose cycle, on day 1 of the first dose cycle, on day 1 of each subsequent dose cycle, and at the end of study or end of dosing, beginning within 15 days after the last dose. c. Height on days -7 to -1 prior to the start of the first dose cycle d. Body weight on days -7 to -1 prior to the start of the first dose cycle, on day 1 of the first dose cycle, on day 1 of each subsequent dose cycle, and at the end of the study or end of dosing, within 15 days after the last dose. e. Vital signs on days -7 to -1 prior to the start of the first dose cycle, on days 1 and 15 of the first dose cycle, on day 1 of each subsequent dose cycle, and at the end of the study or end of dosing, within 15 days after the last dose. iv. Laboratory evaluation Hematology on days -7 to -1 prior to the start of the first dose cycle, on days 8±2 and 15 of the first dose cycle, on day 1 of each subsequent dose cycle, and at the end of the study or end of dosing, within 15 days after the last dose. b. Chemistry on days -7 to -1 prior to the start of the first dose cycle, on days 8±2 and 15 of the first dose cycle, on day 1 of each subsequent dose cycle, and at the end of the study or end of dosing, within 15 days after the last dose. c. Fasting lipid panel on days -7 to -1 prior to the start of the first dose cycle and at the end of study or end of dosing within 15 days after the last dose d. Fasting glucose on days -7 to -1 prior to the start of the first dose cycle and at the end of the study or end of dosing within 15 days after the last dose e. Coagulation events on days -7 to -1 prior to the start of the first dose cycle and at the end of the study or end of dosing within 15 days after the last dose. f. Urinalysis on days -7 to -1 prior to the start of the first dose cycle, on day 1 of dose cycle 2, on day 1 of dose cycle 3, and at the end of the study or end of dosing, within 15 days after the last dose. g. Pregnancy testing on days -7 to -1 prior to the start of the first dose cycle, on day 1 of the first dose cycle, on day 1 of each subsequent dose cycle, and at the end of the study or end of dosing, within 15 days after the last dose. v. Pharmacokinetic and pharmacodynamic evaluation a. Blood collection for PK sampling on day 1 of the first dose cycle, on day 8±2 of the first dose cycle, on day 1 of the second dose cycle, and on the day of the third dose cycle b. Blood collection for PD sampling on days -7 to -1 prior to the start of the first dose cycle; on days 1, 8±2, 15, and 22 of the first dose cycle, on day 1 of each subsequent dose cycle, and at the end of the study or end of dosing, within 15 days after the last dose. vi. Tumor assessment Tumor assessments (per RECIST v1.1) from days -28 to -1 prior to the start of the first dose cycle and every 8 weeks during the first year of the study, then every 12 weeks thereafter, as well as at the end of the trial or end of dosing, until disease progression, death, consent withdrawal, loss to follow up, or participant / parent decision. If a PR / CR is reported, a confirmatory assessment will be performed in the final 4 weeks after the response was first documented. vii. Heart Assessment a. 12-lead ECG on days -7 to -1 prior to the start of the first dose cycle, on days 1 and 8±2 of the first dose cycle, on day 1 of each subsequent dose cycle for up to 5 cycles, and at the end of the study or end of dosing, within 15 days after the last dose. b. ECHO or MUGA with EF during the treatment phase if clinically indicated according to the investigator viii. Other safety evaluations a. Continuous adverse event and serious adverse event review up to 30 days after the last dose and 30 days after the last dose ix. Study intervention administration Compound (1) Days 1 to 28 of each dose cycle b. Letrozole (2.5 mg orally daily) on days 1-28 of each dose cycle x. Follow-up evaluation At the end of the study or end of dosing, within 15 days after the last dose; during safety follow-up 30 days after the last dose, and at survival follow-up every 12 weeks, collection of information on new anti-cancer treatments, if applicable b. PFS and survival follow-up 30 days after the last dose and every 12 weeks after the end of the study

[0235] Embodiment Embodiment 1. A method of treating hormone receptor positive endometrial cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I). [ka] A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 Ga-NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof.

[0236] Embodiment 2. A method of treating endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I). [ka] A compound of the formula: During the ceremony, - R 1is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 Ga-NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof, The method, wherein the subject has received a treatment other than the compound for endometrial cancer prior to administering.

[0237] Embodiment 3. A method of treating endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I). [ka] A compound of the formula: During the ceremony, - R 1is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 Ga-NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof, The method wherein administering is once daily for at least four weeks.

[0238] Embodiment 4. A method of treating endometrial cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I). [ka] A compound of the formula: During the ceremony, - R 1is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 Ga-NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof, Administering (i) a period of 3 consecutive weeks of once-daily dosing, and ii) A 3-week period immediately followed by 1 week of no treatment The method is a four-week cycle.

[0239] Embodiment 5. A method of treating endometrial cancer in a subject in need thereof, the method comprising: (i) administering to a subject a therapeutically effective amount of a first compound having formula (I) [ka] A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 Ga-NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not A first compound, which is a compound or a pharma- ceutically acceptable salt thereof; and (i) administering to the subject a therapeutically effective amount of a second compound. A method comprising:

[0240] Embodiment 6. A method of treating endometrial cancer in a subject in need of treatment for hormone receptor positive endometrial cancer, comprising orally administering to the subject a solid pharmaceutical composition comprising 40 mg to 500 mg of a compound that is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate; the subject has received a treatment other than the compound for endometrial cancer prior to administering, the treatment is given after the subject is diagnosed with endometrial cancer, and the subject has not responded to the treatment prior to administering; The method, wherein administering comprises orally administering, including once daily administration for three weeks.

[0241] Embodiment 7. A method of treating endometrial cancer in a subject in need thereof, the method comprising: (i) orally administering to a subject between 40 mg and 500 mg of a solid pharmaceutical composition comprising 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate; the subject has received a treatment other than the compound for endometrial cancer prior to administering, the treatment is given after the subject is diagnosed with endometrial cancer, and the subject has not responded to the treatment prior to administering; administering comprises administering orally once daily for three weeks; and (ii) orally administering to the subject a therapeutically effective amount of letrozole. A method comprising:

[0242] Embodiment 8. A method of treating endometrial cancer in a subject in need thereof, the method comprising: (i) orally administering to a subject between 40 mg and 500 mg of a solid pharmaceutical composition comprising 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate; the subject has received a treatment other than the compound for endometrial cancer prior to administering, the treatment is given after the subject is diagnosed with endometrial cancer, and the subject has not responded to the treatment prior to administering; administering comprises administering orally once daily for three weeks; and (ii) orally administering to the subject a therapeutically effective amount of megestrol acetate. A method comprising:

Claims

1. A method of treating hormone receptor positive endometrial cancer in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I). 【Chemistry 24】 A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 -NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof.

2. R 1 The method of claim 1 , wherein is cycloalkyl.

3. R 1 The method of claim 1 , wherein is cyclopentyl.

4. R 2 The method of claim 1 , wherein is CN.

5. R 3 The method of claim 1 , wherein is hydrogen.

6. R 4 -NR 5 R 6 The method of claim 1, wherein

7. R 5 and R 6 The method of claim 6 , wherein one of is hydrogen.

8. R 5 and R 6 The method of claim 6, wherein one of is phenyl.

9. R 5 and R 6 The method of claim 6 , wherein one of is phenyl substituted with heterocyclyl.

10. R 5 and R 6 The method of claim 6, wherein one of is phenyl substituted with piperazinyl.

11. R 5 and R 6 The method of claim 6, wherein one of is phenyl substituted with 4-methylpiperazinyl.

12. R 4 but, 【Chemistry 25】 and During the ceremony, - R 7 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen; - R 8 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen; - R 9 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen. The method of claim 1.

13. R 7 The method of claim 12 , wherein is hydrogen.

14. R 8 The method of claim 12 , wherein is hydrogen.

15. R 9 The method of claim 12, wherein is unsubstituted or substituted heterocyclyl.

16. R 9 The method of claim 12, wherein is unsubstituted or substituted piperazinyl.

17. R 9 The method of claim 12, wherein is 4-methylpiperazinyl.

18. The compound is represented by formula (II) 【Chemistry 26】 The method of claim 12, wherein the compound is

19. The compound has the formula (III) 【Chemistry 27】 is a compound of During the ceremony, Y is O, S or NR 11 and - Each R 10 are independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (which are unsubstituted or substituted, respectively) - R 11 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; - n is 0, 1, 2, 3, 4, 5, 6, 7 or 8, The method of claim 12.

20. R 1 20. The method of claim 19, wherein is cycloalkyl.

21. R 1 20. The method of claim 19, wherein is cyclopentyl.

22. Y is NR 11 20. The method of claim 19, wherein:

23. R 11 The method of claim 22, wherein is alkyl.

24. R 11 The method of claim 22, wherein is methyl.

25. 20. The method of claim 19, wherein n is 0.

26. 2. The method of claim 1, wherein the compound is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof.

27. 27. The method of claim 26, wherein the pharma- ceutically acceptable salt is a monolactate salt.

28. 10. The method of claim 1, wherein the therapeutically effective amount is from about 40 mg to about 500 mg per day.

29. 2. The method of claim 1, wherein the hormone receptor positive endometrial cancer is estrogen receptor positive endometrial cancer.

30. 10. The method of claim 1, wherein the subject has received a treatment other than the compound for the hormone receptor positive endometrial cancer prior to said administering.

31. 31. The method of claim 30, wherein the treatment is administered after the subject is diagnosed with the hormone receptor positive endometrial cancer.

32. 31. The method of claim 30, wherein the subject has failed to respond to the treatment.

33. 31. The method of claim 30, wherein the subject has experienced a recurrence of the hormone receptor positive endometrial cancer following the treatment.

34. 10. The method of claim 1, wherein the administering is oral.

35. 10. The method of claim 1, wherein the administering is intravenous.

36. 10. The method of claim 1, wherein the administering is once daily.

37. 10. The method of claim 1, wherein the administering is once daily for at least four weeks.

38. The administering comprises (i) a period of three consecutive weeks of once-daily administration, and ii) a week of no administration immediately following the three-week period 2. The method of claim 1, wherein the administration is orally in a four week cycle.

39. The administering comprises (i) once daily in the morning for a period of three consecutive weeks, wherein the therapeutically effective amount is from about 40 mg to about 500 mg; and ii) a week of no administration immediately following the three-week period 2. The method of claim 1, wherein the administration is orally in a four week cycle.

40. 10. The method of claim 1, wherein the compound is administered in a pharmaceutical composition, the pharmaceutical composition being in a unit dosage form, the unit dosage form further comprising a pharma- ceutically acceptable excipient.

41. 40. The method of claim 39, wherein the unit dosage form comprises about 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile.

42. 40. The method of claim 39, wherein the unit dosage form comprises about 48.4 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

43. 40. The method of claim 39, wherein the unit dosage form is a capsule.

44. 10. The method of claim 1, wherein said administering occurs in the morning of the first day.

45. The method of claim 1 , wherein the subject is in a fasting state.

46. The method of claim 1 , further comprising administering to the subject a therapeutically effective amount of a second compound.

47. 46. ​​The method of claim 45, wherein the second compound is an estrogen receptor modulator.

48. 46. ​​The method of claim 45, wherein the second compound is an estrogen receptor blocker.

49. 46. ​​The method of claim 45, wherein the second compound is an aromatase inhibitor.

50. 46. ​​The method of claim 45, wherein the second compound is letrozole or a pharma- ceutically acceptable salt thereof.

51. 46. ​​The method of claim 45, wherein the second compound is administered in a pharmaceutical composition, the pharmaceutical composition being in a unit dosage form, the unit dosage form further comprising a pharma- ceutically acceptable excipient.

52. 51. The method of claim 50, wherein the unit dosage form comprises about 2.5 mg of letrozole.

53. 52. The method of claim 51, wherein the unit dosage form is a tablet.

54. 47. The method of claim 46, wherein the second compound is a progestin.

55. 55. The method of claim 54, wherein the progestin is megestrol acetate.

56. 56. The method of claim 55, wherein the megestrol acetate is administered in a pharmaceutical composition, the pharmaceutical composition being in a unit dosage form, and the unit dosage form comprising a pharma- ceutically acceptable excipient.

57. 57. The method of claim 56, wherein the unit dosage form comprises about 125 mg / mL megestrol acetate.

58. 57. The method of claim 56, wherein the unit dosage form is an oral suspension.

59. 57. The method of claim 56, wherein the megestrol acetate is administered at a dosage of about 625 mg per day.

60. 47. The method of claim 46, wherein said administration of said second compound is once daily.

61. 47. The method of claim 46, wherein the second compound is a selective estrogen receptor degrader.

62. 47. The method of claim 46, wherein the second compound is a vascular endothelial growth factor inhibitor.

63. 47. The method of claim 46, wherein the second compound is a phosphoinositide 3-kinase inhibitor.

64. 47. The method of claim 46, wherein the administration of the second compound is oral.

65. 47. The method of claim 46, wherein said administration of said second compound is intravenous.

66. 47. The method of claim 46, wherein the administration of the compound of formula (I) is oral and the administration of the second compound is oral.

67. 47. The method of claim 46, wherein said administration of said compound of formula (I) precedes said administration of said second compound.

68. 47. The method of claim 46, wherein said administration of said second compound precedes said administration of said compound of formula (I).

69. 47. The method of claim 46, wherein said administration of said compound of formula (I) is simultaneous with said administration of said second compound.

70. A method of treating endometrial cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I). 【Chemistry 28】 A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 -NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof, The method, wherein the subject has received a treatment for the endometrial cancer other than the compound prior to the administering.

71. R 1 71. The method of claim 70, wherein is cycloalkyl.

72. R 1 is cyclopentyl.

73. R 2 The method of claim 70, wherein is CN.

74. R 3 71. The method of claim 70, wherein is hydrogen.

75. R 4 -NR 5 R 6 71. The method of claim 70, wherein:

76. R 5 and R 6 76. The method of claim 75, wherein one of is hydrogen.

77. R 5 and R 6 76. The method of claim 75, wherein one of is phenyl.

78. R 5 and R 6 76. The method of claim 75, wherein one of is phenyl substituted with heterocyclyl.

79. R 5 and R 6 76. The method of claim 75, wherein one of is phenyl substituted with piperazinyl.

80. R 5 and R 6 76. The method of claim 75, wherein one of is phenyl substituted with 4-methylpiperazinyl.

81. R 4 but, 【Chemical 29】 and During the ceremony, - R 7 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen; - R 8 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen; - R 9 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen.

71. The method of claim 70.

82. R 7 82. The method of claim 81 , wherein is hydrogen.

83. R 8 82. The method of claim 81 , wherein is hydrogen.

84. R 9 82. The method of claim 81 , wherein is unsubstituted or substituted heterocyclyl.

85. R 9 82. The method of claim 81, wherein is unsubstituted or substituted piperazinyl.

86. R 9 82. The method of claim 81, wherein is 4-methylpiperazinyl.

87. The compound is represented by formula (II) 【Chemistry 30】 The method of claim 81, wherein the compound is

88. The compound has the formula (III) 【Chemistry 31】 is a compound of During the ceremony, - Y is O, S or NR 11 and - Each R 10 are independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (which are unsubstituted or substituted, respectively) - R 11 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; - n is 0, 1, 2, 3, 4, 5, 6, 7 or 8, 82. The method of claim 81.

89. R 1 89. The method of claim 88, wherein is cycloalkyl.

90. R 1 The method of claim 88, wherein is cyclopentyl.

91. Y is NR 11 89. The method of claim 88, wherein:

92. R 11 92. The method of claim 91 , wherein is alkyl.

93. R 11 92. The method of claim 91 , wherein is methyl.

94. 89. The method of claim 88, wherein n is 0.

95. 71. The method of claim 70, wherein the compound is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof.

96. 96. The method of claim 95, wherein the compound is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

97. 71. The method of claim 70, wherein the therapeutically effective amount is from about 40 mg to about 500 mg per day.

98. 71. The method of claim 70, wherein the endometrial cancer is hormone receptor positive endometrial cancer.

99. 99. The method of claim 98, wherein the hormone receptor positive endometrial cancer is estrogen receptor positive endometrial cancer.

100. 71. The method of claim 70, wherein the treatment is administered after the subject is diagnosed with the hormone receptor positive endometrial cancer.

101. 71. The method of claim 70, wherein the subject has failed to respond to the treatment.

102. 71. The method of claim 70, wherein the subject experiences a recurrence of the endometrial cancer following the treatment.

103. 71. The method of claim 70, wherein the administering is oral.

104. 71. The method of claim 70, wherein the administering is intravenous.

105. 71. The method of claim 70, wherein the administering is once daily.

106. 71. The method of claim 70, wherein the administering is once daily for at least four weeks.

107. The administering comprises (i) a period of three consecutive weeks of once-daily administration, and ii) a week of no administration immediately following the three-week period 71. The method of claim 70, wherein the administration is oral in a four week cycle.

108. The administering comprises (i) once daily in the morning for a period of three consecutive weeks, wherein the therapeutically effective amount is from about 40 mg to about 500 mg; and ii) a week of no administration immediately following the three-week period 71. The method of claim 70, wherein the administration is oral in a four week cycle.

109. 71. The method of claim 70, wherein the compound is administered in a pharmaceutical composition, the pharmaceutical composition being in a unit dosage form, the unit dosage form further comprising a pharma- ceutically acceptable excipient.

110. 110. The method of claim 109, wherein the unit dosage form comprises about 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile.

111. 102. The method of claim 101, wherein the unit dosage form comprises about 48.4 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

112. 102. The method of claim 101, wherein the unit dosage form is a capsule.

113. 71. The method of claim 70, wherein said administering occurs in the morning of the first day.

114. 71. The method of claim 70, wherein the subject is in a fasted state.

115. 71. The method of claim 70, further comprising administering to the subject a therapeutically effective amount of a second compound.

116. 116. The method of claim 115, wherein the second compound is an estrogen receptor modulator.

117. 116. The method of claim 115, wherein the second compound is an estrogen receptor blocker.

118. 116. The method of claim 115, wherein the second compound is an aromatase inhibitor.

119. 116. The method of claim 115, wherein the second compound is letrozole or a pharma- ceutically acceptable salt thereof.

120. 116. The method of claim 115, wherein the second compound is administered in a pharmaceutical composition, the pharmaceutical composition being in a unit dosage form, and the unit dosage form further comprising a pharma- ceutically acceptable excipient.

121. 121. The method of claim 120, wherein the unit dosage form comprises about 2.5 mg of letrozole.

122. 121. The method of claim 120, wherein the unit dosage form is a tablet.

123. 114. The method of claim 113, wherein the second compound is a progestin.

124. 124. The method of claim 123, wherein the progestin is megestrol acetate.

125. 125. The method of claim 124, wherein the megestrol acetate is administered in a pharmaceutical composition, the pharmaceutical composition being in a unit dosage form, and the unit dosage form comprising a pharma- ceutically acceptable excipient.

126. 126. The method of claim 125, wherein the unit dosage form comprises about 125 mg / mL megestrol acetate.

127. 126. The method of claim 125, wherein the unit dosage form is an oral suspension.

128. 126. The method of claim 125, wherein the megestrol acetate is administered at a dosage of about 625 mg per day.

129. 116. The method of claim 115, wherein the administration of the second compound is once a day.

130. 116. The method of claim 115, wherein the second compound is a selective estrogen receptor degrader.

131. 116. The method of claim 115, wherein the second compound is a vascular endothelial growth factor inhibitor.

132. 116. The method of claim 115, wherein the second compound is a phosphoinositide 3-kinase inhibitor.

133. 116. The method of claim 115, wherein the administration of the second compound is oral.

134. 116. The method of claim 115, wherein the administration of the second compound is intravenous.

135. 116. The method of claim 115, wherein the administration of the compound of formula (I) is oral and the administration of the second compound is oral.

136. 116. The method of claim 115, wherein the administration of the compound of formula (I) precedes the administration of the second compound.

137. 116. The method of claim 115, wherein the administration of the second compound precedes the administration of the compound of formula (I).

138. 116. The method of claim 115, wherein the administration of the compound of formula (I) is simultaneous with the administration of the second compound.

139. A method of treating endometrial cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I). 【Chemistry 32】 A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 -NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof, The method, wherein said administering is once daily for at least four weeks.

140. R 1 is cycloalkyl.

141. R 1 is cyclopentyl.

142. R 2 The method of claim 139, wherein is CN.

143. R 3 The method of claim 139, wherein is hydrogen.

144. R 4 -NR 5 R 6 The method of claim 139,

145. R 5 and R 6 The method of claim 144, wherein one of is hydrogen.

146. R 5 and R 6 The method of claim 144, wherein one of is phenyl.

147. R 5 and R 6 The method of claim 144, wherein one of is phenyl substituted with heterocyclyl.

148. R 5 and R 6 The method of claim 144, wherein one of is phenyl substituted with piperazinyl.

149. R 5 and R 6 is phenyl substituted with 4-methylpiperazinyl.

150. R 4 but, 【Chemical Formula 33】 and During the ceremony, - R 7 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen; - R 8 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen; - R 9 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen. The method of claim 139.

151. R 7 The method of claim 150, wherein is hydrogen.

152. R 8 The method of claim 150, wherein is hydrogen.

153. R 9 is unsubstituted or substituted heterocyclyl.

154. R 9 151. The method of claim 150, wherein is unsubstituted or substituted piperazinyl.

155. R 9 The method of claim 150, wherein is 4-methylpiperazinyl.

156. The compound is represented by formula (II) 【Chemical 34】 The method of claim 150, wherein the compound is

157. The compound has the formula (III) 【Chemistry 35】 is a compound of During the ceremony, Y is O, S or NR 11 and - Each R 10 are independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (which are unsubstituted or substituted, respectively) - R 11 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; - n is 0, 1, 2, 3, 4, 5, 6, 7 or 8, The method of claim 150.

158. R 1 The method of claim 157, wherein is cycloalkyl.

159. R 1 The method of claim 157, wherein is cyclopentyl.

160. Y is NR 11 The method of claim 157, wherein:

161. R 11 The method of claim 160, wherein is alkyl.

162. R 11 The method of claim 160, wherein is methyl.

163. 158. The method of claim 157, wherein n is 0.

164. 140. The method of claim 139, wherein the compound is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof.

165. 165. The method of claim 164, wherein the compound is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

166. 140. The method of claim 139, wherein the therapeutically effective amount is from about 40 mg to about 500 mg per day.

167. 140. The method of claim 139, wherein the endometrial cancer is hormone receptor positive endometrial cancer.

168. 168. The method of claim 167, wherein the hormone receptor positive endometrial cancer is estrogen receptor positive endometrial cancer.

169. 140. The method of claim 139, wherein the subject has received a treatment for the endometrial cancer other than the compound prior to said administering.

170. 170. The method of claim 169, wherein the treatment is administered after the subject is diagnosed with endometrial cancer.

171. 170. The method of claim 169, wherein the subject has failed to respond to the treatment.

172. 170. The method of claim 169, wherein the subject experiences a recurrence of the endometrial cancer following the treatment.

173. 140. The method of claim 139, wherein the administering is oral.

174. 140. The method of claim 139, wherein the administering is intravenous.

175. 140. The method of claim 139, wherein the compound is administered in a pharmaceutical composition, the pharmaceutical composition is in a unit dosage form, and the unit dosage form further comprises a pharma- ceutically acceptable excipient.

176. 176. The method of claim 175, wherein the unit dosage form comprises about 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile.

177. 176. The method of claim 175, wherein the unit dosage form comprises about 48.4 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

178. 176. The method of claim 175, wherein the unit dosage form is a capsule.

179. 140. The method of claim 139, wherein the administering occurs in the morning of the first day.

180. 140. The method of claim 139, wherein the subject is in a fasting state.

181. 140. The method of claim 139, further comprising administering to the subject a therapeutically effective amount of a second compound.

182. 182. The method of claim 181, wherein the second compound is an estrogen receptor modulator.

183. 182. The method of claim 181, wherein the second compound is an estrogen receptor blocker.

184. 182. The method of claim 181, wherein the second compound is an aromatase inhibitor.

185. 182. The method of claim 181, wherein the second compound is letrozole or a pharma- ceutically acceptable salt thereof.

186. 182. The method of claim 181, wherein the second compound is administered in a pharmaceutical composition, the pharmaceutical composition being in a unit dosage form, and the unit dosage form further comprising a pharma- ceutically acceptable excipient.

187. The method of claim 186, wherein the unit dosage form comprises about 2.5 mg of letrozole.

188. 187. The method of claim 186, wherein the unit dosage form is a tablet.

189. 179. The method of claim 178, wherein the second compound is a progestin.

190. 190. The method of claim 189, wherein the progestin is megestrol acetate.

191. The method of claim 190, wherein the megestrol acetate is administered in a pharmaceutical composition, the pharmaceutical composition is in a unit dosage form, and the unit dosage form comprises a pharma- ceutically acceptable excipient.

192. 192. The method of claim 191, wherein the unit dosage form comprises about 125 mg / mL megestrol acetate.

193. 192. The method of claim 191, wherein the unit dosage form is an oral suspension.

194. 192. The method of claim 191, wherein the megestrol acetate is administered at a dosage of about 625 mg per day.

195. 182. The method of claim 181, wherein the administration of the second compound is once a day.

196. 182. The method of claim 181, wherein the second compound is a selective estrogen receptor degrader.

197. 182. The method of claim 181, wherein the second compound is a vascular endothelial growth factor inhibitor.

198. 182. The method of claim 181, wherein the second compound is a phosphoinositide 3-kinase inhibitor.

199. 182. The method of claim 181, wherein the administration of the second compound is oral.

200. 182. The method of claim 181, wherein the administration of the second compound is intravenous.

201. 182. The method of claim 181, wherein the administration of the compound of formula (I) is oral and the administration of the second compound is oral.

202. 182. The method of claim 181, wherein the administration of the compound of formula (I) precedes the administration of the second compound.

203. 182. The method of claim 181, wherein the administration of the second compound precedes the administration of the compound of formula (I).

204. 182. The method of claim 181, wherein the administration of the compound of formula (I) is simultaneous with the administration of the second compound.

205. A method of treating endometrial cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I). 【Chemical 36】 A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 -NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not compound or a pharma- ceutically acceptable salt thereof, The administering comprises (i) a period of three consecutive weeks of once-daily administration, and ii) a week of no administration immediately following the three-week period The method is a four week cycle.

206. R 1 The method of claim 205, wherein is cycloalkyl.

207. R 1 The method of claim 205, wherein is cyclopentyl.

208. R 2 The method of claim 205, wherein is CN.

209. R 3 The method of claim 205, wherein is hydrogen.

210. R 4 -NR 5 R 6 The method of claim 205,

211. R 5 and R 6 The method of claim 210, wherein one of is hydrogen.

212. R 5 and R 6 The method of claim 210, wherein one of is phenyl.

213. R 5 and R 6 The method of claim 210, wherein one of is phenyl substituted with heterocyclyl.

214. R 5 and R 6 The method of claim 210, wherein one of is phenyl substituted with piperazinyl.

215. R 5 and R 6 is phenyl substituted with 4-methylpiperazinyl.

216. R 4 but, 【Chemical 37】 and During the ceremony, - R 7 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen; - R 8 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen; - R 9 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen. The method of claim 205.

217. R 7 The method of claim 216, wherein is hydrogen.

218. R 8 The method of claim 216, wherein is hydrogen.

219. R 9 is unsubstituted or substituted heterocyclyl.

220. R 9 The method of claim 216, wherein is unsubstituted or substituted piperazinyl.

221. R 9 The method of claim 216, wherein is 4-methylpiperazinyl.

222. The compound is represented by formula (II) 【Chemical Formula 38】 The method of claim 216, wherein the compound is

223. The compound has the formula (III) 【Chemical 39】 is a compound of During the ceremony, - Y is O, S or NR 11 and - Each R 10 are independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (which are unsubstituted or substituted, respectively) - R 11 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; - n is 0, 1, 2, 3, 4, 5, 6, 7 or 8, The method of claim 216.

224. R 1 The method of claim 223, wherein is cycloalkyl.

225. R 1 is cyclopentyl.

226. Y is NR 11 The method of claim 223, wherein:

227. R 11 The method of claim 226, wherein is alkyl.

228. R 11 The method of claim 226, wherein is methyl.

229. 224. The method of claim 223, wherein n is 0.

230. 206. The method of claim 205, wherein said compound is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof.

231. 231. The method of claim 230, wherein the compound is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

232. The method of claim 205, wherein the therapeutically effective amount is from about 40 mg to about 500 mg per day.

233. 206. The method of claim 205, wherein the endometrial cancer is hormone receptor positive endometrial cancer.

234. 206. The method of claim 205, wherein the hormone receptor positive endometrial cancer is estrogen receptor positive endometrial cancer.

235. The method of claim 205, wherein the subject has received a treatment other than the compound for the endometrial cancer prior to said administering.

236. 236. The method of claim 235, wherein the treatment is administered after the subject is diagnosed with endometrial cancer.

237. 236. The method of claim 235, wherein the subject has failed to respond to the treatment.

238. The method of claim 235, wherein the subject has experienced a recurrence of the endometrial cancer following the treatment.

239. 206. The method of claim 205, wherein the administering is oral.

240. 206. The method of claim 205, wherein the administering is intravenous.

241. The method of claim 205, wherein the compound is administered in a pharmaceutical composition, the pharmaceutical composition is in a unit dosage form, and the unit dosage form further comprises a pharma- ceutically acceptable excipient.

242. The method of claim 241, wherein the unit dosage form comprises about 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile.

243. The method of claim 241, wherein the unit dosage form comprises about 48.4 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

244. 242. The method of claim 241, wherein the unit dosage form is a capsule.

245. The method of claim 205, wherein said administering occurs in the morning of the first day.

246. The method of claim 205, wherein the subject is in a fasting state.

247. 206. The method of claim 205, further comprising administering to the subject a therapeutically effective amount of a second compound.

248. 248. The method of claim 247, wherein the second compound is an estrogen receptor modulator.

249. 248. The method of claim 247, wherein the second compound is an estrogen receptor blocker.

250. 248. The method of claim 247, wherein the second compound is an aromatase inhibitor.

251. 248. The method of claim 247, wherein the second compound is letrozole or a pharma- ceutically acceptable salt thereof.

252. The method of claim 247, wherein the second compound is administered in a pharmaceutical composition, the pharmaceutical composition is in a unit dosage form, and the unit dosage form further comprises a pharma- ceutically acceptable excipient.

253. The method of claim 252, wherein the unit dosage form comprises about 2.5 mg of letrozole.

254. 253. The method of claim 252, wherein the unit dosage form is a tablet.

255. 248. The method of claim 247, wherein the second compound is a progestin.

256. The method of claim 255, wherein the progestin is megestrol acetate.

257. The method of claim 256, wherein the megestrol acetate is administered in a pharmaceutical composition, the pharmaceutical composition is in a unit dosage form, and the unit dosage form comprises a pharma- ceutically acceptable excipient.

258. The method of claim 257, wherein the unit dosage form comprises about 125 mg / mL megestrol acetate.

259. The method of claim 257, wherein the unit dosage form is an oral suspension.

260. The method of claim 257, wherein the megestrol acetate is administered at a dosage of about 625 mg per day.

261. 248. The method of claim 247, wherein the administration of the second compound is once a day.

262. The method of claim 247, wherein the second compound is a selective estrogen receptor degrader.

263. 248. The method of claim 247, wherein the second compound is a vascular endothelial growth factor inhibitor.

264. 248. The method of claim 247, wherein the second compound is a phosphoinositide 3-kinase inhibitor.

265. 248. The method of claim 247, wherein the administration of the second compound is oral.

266. 248. The method of claim 247, wherein the administration of the second compound is intravenous.

267. 248. The method of claim 247, wherein the administration of the compound of formula (I) is oral and the administration of the second compound is oral.

268. 248. The method of claim 247, wherein the administration of the compound of formula (I) precedes the administration of the second compound.

269. The method of claim 247, wherein the administration of the second compound precedes the administration of the compound of formula (I).

270. 248. The method of claim 247, wherein the administration of the compound of formula (I) is simultaneous with the administration of the second compound.

271. 1. A method of treating hormone receptor positive endometrial cancer in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically effective amount of a first compound having formula (I) 【Chemistry 40】 A compound of the formula: During the ceremony, - R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen; - R 2 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -CN, -C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen; - R 4 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -CN, C(O)R 5 , -C(O)OR 5 , -C(O)NR 5 R 6 , -C(=N)NR 5 R 6 , -OR 5 , -SR 5 , -NR 5 R 6 , -NR 5 C(O)R 6 , -NR 5 C(O)OR 6 , -OC(O)R 5 , -OC(O)NR 5 R 6 , -S(O) 2 R 5 , -NHS(O) 2 R 5 Or -OS(O) 2 R 5 (each of which is independently substituted or unsubstituted), or hydrogen or halogen; - Each R 5 and R 6 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; However, R 4 -NR 5 R 6 and R 5 and R 6 When one of R is pyridyl, R 2 -C(O)CH 3 provided that it is not A first compound, which is a compound or a pharma- ceutically acceptable salt thereof; and (ii) administering to said subject a therapeutically effective amount of a second compound. A method comprising:

272. R 1 The method of claim 271, wherein is cycloalkyl.

273. R 1 The method of claim 271, wherein is cyclopentyl.

274. R 2 The method of claim 271, wherein is CN.

275. R 3 The method of claim 271, wherein is hydrogen.

276. R 4 -NR 5 R 6 The method of claim 271,

277. R 5 and R 6 277. The method of claim 276, wherein one of is hydrogen.

278. R 5 and R 6 The method of claim 276, wherein one of is phenyl.

279. R 5 and R 6 The method of claim 276, wherein one of is phenyl substituted with heterocyclyl.

280. R 5 and R 6 The method of claim 276, wherein one of is phenyl substituted with piperazinyl.

281. R 5 and R 6 The method of claim 276, wherein one of is phenyl substituted with 4-methylpiperazinyl.

282. R 4 but, 【Chemistry 41】 and During the ceremony, - R 7 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen; - R 8 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen; - R 9 is an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (each of which is unsubstituted or substituted), or hydrogen. The method of claim 271.

283. R 7 The method of claim 282, wherein is hydrogen.

284. R 8 The method of claim 282, wherein is hydrogen.

285. R 9 The method of claim 282, wherein is unsubstituted or substituted heterocyclyl.

286. R 9 The method of claim 282, wherein is unsubstituted or substituted piperazinyl.

287. R 9 The method of claim 282, wherein is 4-methylpiperazinyl.

288. The compound is represented by formula (II) 【Chemistry 42】 The method of claim 282, wherein the compound is

289. The compound has the formula (III) 【Chemistry 43】 is a compound of During the ceremony, Y is O, S or NR 11 and - Each R 10 are independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 Or -NR 5 R 6 (which are unsubstituted or substituted, respectively) - R 11 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; - n is 0, 1, 2, 3, 4, 5, 6, 7 or 8, The method of claim 282.

290. R 1 The method of claim 289, wherein is cycloalkyl.

291. R 1 The method of claim 289, wherein is cyclopentyl.

292. Y is NR 11 The method of claim 289,

293. R 11 The method of claim 292, wherein is alkyl.

294. R 11 The method of claim 292, wherein is methyl.

295. 290. The method of claim 289, wherein n is 0.

296. 272. The method of claim 271, wherein the first compound is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharma- ceutically acceptable salt thereof.

297. 300. The method of claim 296, wherein the first compound is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

298. 272. The method of claim 271, wherein the therapeutically effective amount is from about 40 mg to about 500 mg per day.

299. 272. The method of claim 271, wherein the endometrial cancer is hormone receptor positive endometrial cancer.

300. 272. The method of claim 271, wherein the endometrial cancer is estrogen receptor positive endometrial cancer.

301. The method of claim 271, wherein the subject has received a treatment other than the compound for the endometrial cancer prior to the administration of the first compound and prior to the administration of the second compound.

302. The method of claim 301, wherein the treatment is administered after the subject has been diagnosed with endometrial cancer.

303. The method of claim 301, wherein the subject has not responded to the treatment.

304. The method of claim 301, wherein the subject has experienced a recurrence of the endometrial cancer following the treatment.

305. 272. The method of claim 271, wherein the administration of the first compound is oral.

306. 272. The method of claim 271, wherein the administration of the first compound is intravenous.

307. 272. The method of claim 271, wherein the administration of the first compound is once a day.

308. 272. The method of claim 271, wherein said administration of said first compound is once a day for at least four weeks.

309. said administering of said first compound comprises: (i) a period of three consecutive weeks of once-daily administration, and ii) a week of no administration immediately following the three-week period The method of claim 271, wherein the administration is orally in a four week cycle.

310. said administering of said first compound comprises: (i) a period of three consecutive weeks of administration once daily in the morning, wherein the therapeutically effective amount is from about xx to about yy; and ii) a week of no administration immediately following the three-week period The method of claim 271, wherein the administration is orally in a four week cycle.

311. The method of claim 271, wherein the first compound is administered in a pharmaceutical composition, the pharmaceutical composition is in a unit dosage form, and the unit dosage form further comprises a pharma- ceutically acceptable excipient.

312. The method of claim 271, wherein the first compound is administered in a pharmaceutical composition, the pharmaceutical composition is in a unit dosage form, and the unit dosage form further comprises a pharma- ceutically acceptable excipient.

313. The method of claim 312, wherein the unit dosage form comprises about 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile.

314. The method of claim 312, wherein the unit dosage form comprises about 48.4 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.

315. 313. The method of claim 312, wherein the unit dosage form is a capsule.

316. 272. The method of claim 271, wherein the administering occurs in the morning of the first day.

317. 272. The method of claim 271, wherein the subject is in a fasting state.

318. 272. The method of claim 271, wherein the second compound is an estrogen receptor modulator.

319. 272. The method of claim 271, wherein the second compound is an estrogen receptor blocker.

320. 272. The method of claim 271, wherein the second compound is an aromatase inhibitor.

321. 272. The method of claim 271, wherein the second compound is letrozole or a pharma- ceutically acceptable salt thereof.

322. The method of claim 271, wherein the second compound is administered in a pharmaceutical composition, the pharmaceutical composition is in a unit dosage form, and the unit dosage form further comprises a pharma- ceutically acceptable excipient.

323. The method of claim 322, wherein the unit dosage form comprises about 2.5 mg of letrozole.

324. 323. The method of claim 322, wherein the unit dosage form is a tablet.

325. 272. The method of claim 271, wherein the second compound is a progestin.

326. The method of claim 325, wherein the progestin is megestrol acetate.

327. The method of claim 326, wherein the megestrol acetate is administered in a pharmaceutical composition, the pharmaceutical composition is in a unit dosage form, and the unit dosage form comprises a pharma- ceutically acceptable excipient.

328. The method of claim 327, wherein the unit dosage form comprises about 125 mg / mL megestrol acetate.

329. The method of claim 327, wherein the unit dosage form is an oral suspension.

330. The method of claim 327, wherein the megestrol acetate is administered at a dosage of about 625 mg per day.

331. 272. The method of claim 271, wherein the administration of the second compound is once a day.

332. The method of claim 271, wherein the second compound is a selective estrogen receptor degrader.

333. 272. The method of claim 271, wherein the second compound is a vascular endothelial growth factor inhibitor.

334. 272. The method of claim 271, wherein the second compound is a phosphoinositide 3-kinase inhibitor.

335. 272. The method of claim 271, wherein the administration of the second compound is oral.

336. 272. The method of claim 271, wherein the administration of the second compound is intravenous.

337. 272. The method of claim 271, wherein the administration of the first compound is oral and the administration of the second compound is oral.

338. 272. The method of claim 271, wherein the administration of the first compound precedes the administration of the second compound.

339. 272. The method of claim 271, wherein the administration of the second compound precedes the administration of the first compound.

340. 272. The method of claim 271, wherein the administration of the first compound is simultaneous with the administration of the second compound.

341. 1. A method of treating endometrial cancer in a subject in need of such treatment, comprising orally administering to the subject a solid pharmaceutical composition comprising 40 mg to 500 mg of a compound that is 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate; the subject has received a treatment other than the compound for the endometrial cancer prior to said administering, the treatment being given after the subject has been diagnosed with endometrial cancer, and the subject has not responded to the treatment prior to said administering; orally administering, said administering comprising once daily administration for three weeks. A method comprising:

342. 1. A method of treating endometrial cancer in a subject in need thereof, the method comprising: (i) orally administering to the subject 40 mg to 500 mg of a solid pharmaceutical composition comprising 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate; the subject has received a treatment other than the compound for the endometrial cancer prior to said administering, the treatment being given after the subject has been diagnosed with endometrial cancer, and the subject has not responded to the treatment prior to said administering; orally, wherein the administering comprises administering once a day for three weeks; and (ii) orally administering to the subject a therapeutically effective amount of letrozole. A method comprising:

343. 1. A method of treating endometrial cancer in a subject in need thereof, the method comprising: (i) orally administering to the subject 40 mg to 500 mg of a solid pharmaceutical composition comprising 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate; the subject has received a treatment other than the compound for the endometrial cancer prior to said administering, the treatment being given after the subject has been diagnosed with endometrial cancer, and the subject has not responded to the treatment prior to said administering; orally, wherein the administering comprises administering once a day for three weeks; and (ii) orally administering to the subject a therapeutically effective amount of megestrol acetate. A method comprising: